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8ABStRACt
Orexin A and orexin B are hypothalamic 
neuropeptides secreted by a relatively small group 
of neurons located within the hypothalamus. 
Orexins bind and activate two G-protein-coupled 
receptors termed OX1 orexin receptor and OX2 
orexin receptor. They regulate several physiological 
processes including arousal and the sleep/wake 
cycle, endocrine functions, and feeding and energy 
metabolism. 
Previous studies have established calcium as 
the central second messenger of the OX1 receptor. 
Stimulation of OX1 leads to increased intracellular 
Ca2+ release via the classical phospholipase 
C/inositol-1,4,5-trisphosphate pathway, and 
subsequently also store-operated Ca2+ entry. In 
addition, OX1 activation triggers receptor-operated 
Ca2+ entry by a mechanism not completely 
understood. Other intracellular signals originating 
from the OX1 receptor include the activation of 
many signaling enzymes such as protein kinase C, 
extracellular signal-regulated kinase 1/2 (ERK1/2) 
and phospholipase D.
The role of phospholipase A2 (PLA2) in OX1 
signal transduction was investigated in this thesis. 
Recombinant Chinise Hamster Ovary-K1 and 
Human Embryonic Kidney 293 cells were used for 
the studies. Orexin A binding induced robust release 
of arachidonic acid (AA). The enzyme species 
responsible for AA release was suggested to be 
cytocolic PLA2α. AA release was highly dependent 
on extracellular Ca2+ and partly on the activation 
of ERK. The involvement of other PLA2 enzymes 
was ruled out by pharmacological analysis. cPLA2 
activity was also shown to regulate receptor-operated 
Ca2+ entry, but the exact nature of the relaying signal 
remained unspecified. Thin layer chromatography 
analysis revealed that orexin-A stimulation also 
induced the production of 2-arachidonyl glycerol 
(2-AG), an endocannabinoid, via the phospholipase 
C-diacylglycerol lipase pathway. OX1-induced 
2-AG production occurred at a biologically 
relevant magnitude as judged by an artificial cell-
cell communication assay developed, establishing 
the postulated link between orexinergic and 
endocannabinoid systems.
One part of this research aimed at devising faster 
ways to assess AA release. As a result, a filtration-
based method suitable for agonist screening was 
developed. A filtration method for AA release enables 
increased sample throughput with lower noise.
In this study, two new signaling components, AA 
and 2-AG, originating from OX1 receptor signaling 
were identified and the enzymatic species responsible 
were shown to be cPLA2 and diacylglycerol lipase. 
These findings are important for mapping of the 
cellular and molecular functions of orexins and their 
receptors, especially in the central nervous system.
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[Ca2+]i  Cytoplasmic Ca
2+ concentration
2-AG 2-arachidonyl glycerol
aa  Amino acid
AA  Arachidonic acid
AC  Adenylyl cyclase
ARC  Arachidonic acid regulated channel
BSA  Bovine serum albumin
CB1 CB1 cannabinoid receptor
CB2 CB2 cannabinoid receptor
CCK  Cholecystokinin
CCP  Clathrin-coated pit
CNS  Central nervous system
DAG  Diacylglycerol
DAGK  Diacylglycerol kinase
DAGL  Diacylglycerol lipase
DMV  Dorsal motor nucleus of vagus
DRN  Dorsal raphe nucleus
eCB  Endocannabinoid
ECS  Endocannabinoid system
ENS  Enteric nervous system
ER  Endoplasmic reticulum
ERK  Extracellular signal-regulated kinase
FAAH  Fatty acid amide hydrolase
GEF  Guanine nucleotide exchange factor
GIT  Gastrointestinal tract
GPCR  G-protein-coupled receptor
GP-NAE  Glycerophospho N-acetylethanolamine
GRK  GPCR kinase
HBM  Hepes-buffered medium
IP3  Inositol-1,4,5-trisphosphate
IP3R  Inositol-1,4,5-trisphosphate Receptor
LC  Locus coeruleus
LHA  Lateral hypothalamic area
LPA  Lysophosphatic acid
MAFP  Methoxyarachidonyl fluorophosponate
MAG  Monoacylglycerol
MAGL  Monoacylglycerol lipase
MAPK  Mitogen-activated protein kinase
MEK  MAPK/ERK kinase
NAAA  NAE-hydrolyzing acid amidase
NAT  N-acyltransferase
NPY  Neuropeptide Y
OX1 OX1 orexin receptor
OX2 OX2 orexin receptor
OxA Orexin-A
OxB Orexin-B
PA  Phosphatidic acid
PEAse  Palmitoyl ethanolamidase
PC  Phosphatidylcholine
PE  Phosphatidylethanolamine
PI  Phosphatidylinositol(s)
PI3K  Phosphoinositide 3-kinase
PIP2  Phosphaditylinositol-4,5-bisphosphate
PIP5K  Phosphatidylinositol-4-phosphate 
5-kinase
PKA  Protein kinse A
PKC  Protein kinase C
PL  Phospholipid
PLA2  Phospholipase A2
PLC  Phospholipase C
PLD  Phospholipase D
PPO  Prepro-orexin
PS  Phosphatidylserine
PUFA  Polyunsaturated fatty acid
RGS  Regulator of G-protein signaling
ROC Receptor-operated channel
STIM  Stromal interaction molecule
SOC Store-operated channels
TGN  Trans-Golgi network
THC Δ9-Tetrahydrocannabinol
THL  Tetrahydrolipstatin
TMN  Tuberomammilary nucleus
UTR  Untranslated region
VLPO  Ventrolateral preoptic nucleus
VOC V oltage-operated channels
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1. Review Of the liteRAtuRe
1.1. Introduction
The formation of the first functional cell has been 
one of the most crucial steps in the evolution of life 
in the shape we recognize it. It took millions of years 
until the first cells learned to communicate with each 
other. Communication, or signaling as we like to call 
it, is of utmost importance for the development of 
multicellular and hence more complex life forms.
Signaling is about relaying information forward and 
receiving it in order to create adequate responses. 
It is needed in the very first step of life when a 
sperm is swimming toward the ovum and changing 
direction along the concentration gradients of 
chemoattractants secreted. Signaling is needed in the 
fertilization process, and a large amount of signaling 
is needed during development. Signaling controls 
gene expression, energy metabolism, and finally cell 
death.
In the basic scenario, a cell secretes a signaling 
component or expresses one on its plasma 
membrane. The target cell then detects the signal 
with receiver molecule(s) termed receptors. 
Depending on the chemical nature of the signal, the 
receptor is either located on the plasma membrane 
or lies inside the cell in the cytoplasm or nucleus. 
Water-soluble signal molecules are usually unable to 
penetrate the hydrophobic plasma membrane, and 
bind to receptors located on the plasma membrane. 
The plasma membrane is a selective semi-permeable 
barrier between the interior of the cell and the 
outside solution. Lipid-soluble molecules can easily 
pass through the plasma membrane and bind to their 
receptors in the cytoplasm or nucleus. In many cases, 
ligand binding activates signal transduction cascades 
that alter the behavior of the cell. Activated pathways 
downstream from the receptor often utilize small 
molecules termed second messengers. Ca2+ ions are 
common second messengers, but second messengers 
can also be organic molecules such as cAMP and lipid 
derivatives. The advantage of second messengers is 
their ability to rapidly amplify the signal inside the 
cell.
Occasionally, due to a mutation or several mutations, 
signaling systems become harmful or even deadly 
to the organism. The etiological explanation 
behind numerous diseases, including cancer, is the 
malfunction of signal transduction or regulation. 
Better comprehension of the molecular logic of 
signaling benefits not only basic life science but also 
medicine. With a deeper understanding of disease-
causing signaling pathways, new doors are opened 
for drugs and therapeutic approaches that might 
ultimately lead to the conquering of such diseases.
1.2. Calcium signaling
The calcium ion is the most ubiquitous and universal 
molecule involved in signaling (Clapham, 2007). 
It is utilized by organisms from bacteria to humans 
(Berridge et al., 2000; Clapham, 2007; Norris et al., 
1996). Ca2+ is needed in fertilization and programmed 
cell death, cell division, secretion, neuronal signaling, 
and muscle contraction, among other processes. 
It is intriguing that opposing phenomena such as 
proliferation and apoptosis or vasodilatation and 
vasoconstriction are both regulated by an increase in 
intracellular Ca2+ (Parkash et al., 2010), and yet cells 
are able to distinguish between the signal sources 
and adjust their functions accordingly. The presence 
of Ca2+ in the course of evolution has generated 
structural motifs and proteins that specifically bind 
Ca2+ and couple the binding to conformational 
variations. The most common motif is the so-called 
EF hand, found in several proteins, including the 
ubiquitous Ca2+ sensor calmodulin (CaM) (Lewit-
Bentley et al., 2000). CaM is a dumbbell-shaped 
small protein that undergoes a dramatic change in 
conformation upon Ca2+ binding (Klee et al., 1980).
This shape-shifting (and Ca2+-sensor) ability is 
usually coupled to binding to target proteins and 
regulation of their activity (Klee et al., 1980). Many 
proteins have a Ca2+-binding domain called the C2 
domain embedded into their structure (Hurley, 
2006). The positive charge of Ca2+ allows C2 proteins 
to bind anionic lipids located in the inner leaflet of 
the plasma membrane (Hurley, 2006). Important 
signaling proteins containing the C2 domain 
include protein kinase C (PKC), phosphoinositide 
3-kinase (PI3K), phospholipase A2 (PLA2), and 
synaptotagmin (Clapham, 2007; Hurley, 2006).
The fundamental concept of Ca2+ signaling is outlined 
with a few principles that are sometimes referred to 
as the Ca2+ signaling network or “toolkit” (Berridge et 
al., 2000). It consists of: a) the extracellular stimulus 
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(hormone, neurotransmitter etc.) that activates 
the intracellular Ca2+-mobilizing signals, the “on-
mechanisms” that rapidly leads to an increase in the 
intracellular concentration of calcium, [Ca2+]i, b) 
the cellular processes regulated by Ca2+, and finally 
c) the “off-mechanisms” that remove the Ca2+ from 
the cytoplasm and return the cell to the resting state. 
[Ca2+]i in resting cells is held very low (around 100 
nM) by stringent regulation of Ca2+ localization, 
energy-requiring pumps and transporters that 
transfer Ca2+ across cellular membranes, and Ca2+-
sequestering organelles or molecules (Clapham, 
2007). A low cytoplasmic concentration prevents 
unwanted precipitation of calcium phosphates and 
establishes the framework for varying Ca2+ signal 
amplitude, timing, and localization (Clapham, 
2007).
Extracellular fluid (ECF) contains Ca2+ at 
concentrations several orders of magnitude higher 
(around 1 mM) than the cytoplasmic concentration, 
probably reflecting the composition of ancient 
seas where life developed eons ago. ECF-derived 
Ca2+ is commonly utilized in signal transduction 
cascades (often termed Ca2+ influx). In addition to 
ECF, Ca2+ can be mobilized from intracellular stores 
(Ca2+ release). Mitochondria and the endoplasmic 
reticulum (ER) are the most important cellular 
Ca2+ storage organelles. They participate in signaling 
and buffering of free cytoplasmic Ca2+ (Clapham, 
2007). Cytoplasmic spikes in [Ca2+]i concentrations 
are often referred to as Ca2+ transients, which can 
reach a concentration of 1 µM or higher and relay 
considerable amounts of information within the 
cell. Even more information can be transmitted 
by repetitive Ca2+ transients termed oscillations. 
Single Ca2+ transients usually activate fast cellular 
events such as muscle contraction or exocytosis. 
Oscillations, in turn, regulate more complicated 
processes such as cell division (Clapham, 2007).
1.2.1 Ca2+ influx
Ca2+ influx mainly occurs via channels classified as 
ionotropic receptors (ligand gated ion channels), 
voltage-operated Ca2+ channels (VOCs), receptor-
operated channels (ROCs) and store-operated 
channels (SOCs) according to the opening 
mechanisms of the channels (Clapham, 2007). 
Ionotropic receptors are opened upon extracellular 
ligand binding (Tsien et al., 1990). Excitatory 
ionotropic receptors include receptors for the 
neurotransmitters glutamate (AMPA, kainate, 
NMDA-receptors), acetylcholine (nAChRs), glycine 
(exicatory glycine N1-3 receptors), serotonin (5-HT3 
receptors) and ATP (P2X receptors). Some of these 
non-selective cation channels are also permeable for 
Ca2+ (Hayashi et al., 1996; Rathouz et al., 1994).
VOCs function as transducers converting changes 
in membrane potential into intracellular Ca2+ 
transients (Catterall, 2011). The ten known 
mammalian members are divided according to their 
α-subunit into three classes of Cav1, Cav2 and Cav3 
(Catterall, 2011; Ertel et al., 2000). VOCs are also 
classified according to their electrophysiological (e.g. 
activation voltage, activation/inactivation velocity, 
conductance) and pharmacological properties (e.g. 
sensitivity to inhibitors and toxins) into L- (Cav1), 
N- (Cav2.1), P/Q- (Cav2.2), R- (Cav2.3), and T-type 
(Cav3) channels (Catterall, 2011). VOCs are Ca
2+-
specific channels and mostly expressed in excitable 
cells, e.g. neurons, and muscle and endocrine cells. In 
general, VOCs regulate contraction, secretion, and 
gene expression (Catterall, 2011). In muscle cells 
(cardiac, smooth and skeletal muscle), VOCs couple 
to ryanodine receptors either via direct molecular 
contact or indirectly via Ca2+ elevation (Catterall, 
2011). The functions of VOCs in excitation-
contraction/secretion or synaptic transmission-
coupling are tightly regulated by G-protein-
mediated signaling pathways by G-protein subunits 
or phosphorylation (Catterall, 2011).
Receptor-operated channels (ROCs) refer to Ca2+ 
influx pathways that are not voltage-controlled or 
activated by emptying of ER Ca2+ stores (Tsien et 
al., 1990), but rather are activated upon separate 
receptor binding and subsequent intracellular 
signaling. Several intracellular second messengers 
have been implicated in ROC regulation, including 
inositol-1,4,5-trisphosphate (IP3) (Kiselyov et al., 
1997; Mozhayeva et al., 1990), diacylglycerol (DAG) 
(Hofmann et al., 1999), cyclic nucleotides (Finn et al., 
1996), arachidonic acid (AA) (Mignen et al., 2000), 
and G-proteins (Barritt, 1999; Berven et al., 1994; 
Singer-Lahat et al., 1997). The activation of channels 
in receptor signaling may also relate to other processes 
than direct messenger-action, e.g. translocation to the 
plasma membrane or effects on membrane curvature 
(Kukkonen, 2011). Until recently, ROCs were only 
described based on their physiological properties 
without knowledge of their molecular nature 
(Barritt, 1999), but the identification of the transient 
receptor potential (TRP) family of ion channels has 
dramatically changed the field. The “original” TRP 
channel was described in Drosophila TRP mutants 
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(Cosens et al., 1969; Hardie et al., 1992; Minke, 
1982). In a normal Drosophila eye, a light stimulus 
produces a photoreceptor potential composed 
of both a transient and sustained phase, but the 
mutation abolishes the sustained phase (Minke et al., 
2002). The loss of the sustained response was finally 
ascribed by Montell et al. to be an inactivation of a 
Ca2+-permeable channel, coined TRP (Hardie et al., 
1992; Montell et al., 1985; Montell et al., 1989). This 
led to a “cascade” of homology cloning of mammalian 
orthologs, of which we currently know 28 in humans 
divided into the subfamilies TRPC, TRPM, TRPV, 
TRPA, TRPP, and TRPML; however, not all of the 
TRP homologs may function as channels (Nilius 
et al., 2007; Venkatachalam et al., 2007). TRPs are 
Ca2+-permeable nonspecific cation channels that 
share a common structural theme of six membrane-
traversing segments (S1-6) and cytoplasmic N- and 
C-termini. The pore is formed by S5 and S6. The 
functional channel is suggested to be a complex of 
four TRP monomers in either homo- or heteromeric 
assembly (Minke et al., 2002; Montell, 2011).
TRP channels are regulated by multiple signals. 
Most of the mammalian TRP channels require 
PLC activity for functioning. PLC-generated DAG 
directly activates TRPC2, -3, -6, and -7. On the other 
hand, DAG inhibits, indirectly via PKC activation, 
TRPC3, -4, -5, and -6. PLC, phosphaditylinositol-3-
kinase (PI3K), and phospholipase D (PLD) can also 
regulate TRPs by affecting phosphaditylinositol-4,5-
bisphosphate (PIP2) levels in the plasma membrane. 
Various lipids and and lipid derivatives are implicated 
in TRP regulation, including AA and other 
polyunsaturated fatty acids (PUFAs), sphingosine-
1-phosphate, lyso-phosphaditylcholine (LPC), 
platelet-activating factor (PAF), endovanilloids, and 
eicosanoids. (Kukkonen, 2011; Venkatachalam et al., 
2007).
Store-operated Ca2+ entry (SOCE) becomes active 
when ER Ca2+ stores are depleted. Depletion is 
detected by transmembrane ER proteins called 
STIMs (stromal interaction molecule), of which 
two mammalian homologues, STIM1 and STIM2, 
are known (Cahalan, 2009; Zhang et al., 2005). 
STIM1 was already cloned in 1996 (Parker et al., 
1996), but the gene function in SOCE became 
evident much later (Zhang et al., 2005). STIM1 
is the actual Ca2+ censor of the ER, while STIM2 
regulates basal Ca2+ levels (Brandman et al., 2007). 
A decrease in the Ca2+ concentration within the ER 
leads to dissociation of bound Ca2+ from the EF 
hand of STIM1 (Zhang et al., 2005). Dissociation 
initiates STIM1 oligomerization and translocation 
to the junction area between the ER and plasma 
membranes (Liou et al., 2007). STIM1 then interacts 
with specific Ca2+ channels formed by proteins of 
the Orai family (Orai1-3) (Feske et al., 2006). The 
actual molecular mechanism of the interaction is 
not completely known, nor is it known whether the 
interaction is direct or indirect (Smyth et al., 2010), 
but calcium-independent PLA2β (iPLA2β) has 
been suggested to provide the link between STIM1 
and Orai1 (Bolotina, 2008). Opening of the Ora1 
channels leads to Ca2+ influx and replenishment of 
the ER Ca2+ store. In electrophysiology, the current 
passing through Orai1 is known as ICRAC (Zweifach et 
al., 1993), described long before the final discovery 
of Orai1 (Smyth et al., 2010). In addition to Orai1, 
TRPC subfamily channels have been shown to 
mediate SOCE as such or in concert with Orai1 
via interactions with STIM1 (Cheng et al., 2011), 
although this has been questioned in other reports 
(Cheng et al., 2011; DeHaven et al., 2009).
Ca2+ entry may also take place via carrier proteins, 
although this is usually considered much less 
important than channel-mediated entry. The most 
well known example of this is the reverse action of 
the Na+/Ca2+ exchanger (see below).
Ca2+ influx is a (cost-) effective signaling method. 
Highly localized Ca2+ hot-spots can be generated 
in the vicinity of the channels, without any general 
Ca2+ elevation in the cell. The plasma membrane is 
in many ways an important signaling domain, and 
many opportunities for Ca2+ signals to interact with 
other signals are generated.
1.2.2. Ca2+ release
The research of Michael J. Berridge and coworkers 
on the secretion mechanism of the blow-fly salivary 
gland revealed a fundamental signaling pathway 
for Ca2+ release from intracellular stores (reviewed 
by Berridge, 2009). They demonstrated that the 
diffusible agent (second messenger) involved was 
IP3, derived from the highly phosphorylated inositol-
containing phospholipid, phosphatidylinositol-4,5-
bisphosphate (PIP2), by the action of phospholipase 
C (PLC) (Berridge, 1983). Finally, the discovery that 
IP3 acted on receptor channels on the ER membranes 
leading to an increase in [Ca2+]i completed the picture 
(Furuichi et al., 1989; Spat et al., 1986). IP3 binds 
to the cytoplasmic tail of the specific IP3 receptors 
(IP3Rs) located on the ER membranes (Taylor et al., 
2002). These receptors are tetrameric and regulated 
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by both IP3 and Ca
2+ in addition to phosphorylation 
(Bosanac et al., 2004). Three isoforms of IP3Rs are 
known with different tissue-dependent expression 
profiles. IP3Rs themselves are Ca
2+ channels that 
allow Ca2+ to pass from the ER into the cytoplasm 
(Taylor et al., 2002). At lower Ca2+ concentrations, 
Ca2+ promotes the opening of the channel (Bootman 
et al., 1999). In fact, IP3 cannot open the channel 
unless Ca2+ is bound to the structure (Taylor et 
al., 2002). At high concentrations, Ca2+ closes the 
channel (Bootman et al., 1999).
PLC activity also produces another second 
messenger, the lipid remnant of PIP2, namely DAG 
(Rhee, 2001). DAG, in contrast to IP3, remains on 
the plasma membrane, where it diffuses laterally and 
can activate multiple important signaling enzymes, 
including PKC subfamilies c (conventional) and 
n (novel), protein kinase D (PKD), Ras and DAG 
kinases (DGK) β and γ (Baier, 2003; Carrasco et al., 
2007; Kukkonen, 2011).
The PLC family contains 13 members divided into 
six subfamilies (β, γ, δ, ε, η, and ζ) (Bunney et al., 
2011; Rhee, 2001; Suh et al., 2008). In addition, 
two or more splice variants are known for most of 
the PLC family members. The protein repertoire 
together with different tissue distribution, regulatory 
mechanisms and physiological functions make 
PLC signaling very multifaceted (Suh et al., 2008). 
The best characterized are PLCβs (PLCβ1−4) 
and PLCγs (PLCγ1and 2). They were originally 
considered to be activated as a consequence of 
Gq/11 activation (Bunney et al., 2011; Rhee, 2001) 
and by receptor and non-receptor tyrosine kinases, 
respectively (Bunney et al., 2011; Noh et al., 1995), 
but more recently, PLCγ has been found to be 
activated by G-protein-coupled receptors (GPCRs) 
and PLCβs by Rac GTPases (Bunney et al., 2006; 
Bunney et al., 2011). Novel-type PLCε are regulated 
by monomeric G-proteins of Ras and Rho families. 
PLCδ and -ζ appear to be mainly regulated by an 
increase in [Ca2+]i (Kim et al., 1999).
Gα proteins of the Gαq/11 family are the most 
important regulators of PLCβ (Taylor et al., 1991), 
but the Gβγ complex can activate various PLCβ 
isoforms (reviewed in Dupre et al., 2009; Smrcka et 
al., 1993). PLCβs are also subject to phosphorylation 
by protein kinase A (PKA) and PKC (Rebecchi et al., 
2000). An interesting regulatory feature of the PLCβs 
is their ability to function as GTPase-activating 
proteins (GAP) for Gαq/11 proteins (Berstein et al., 
1992; Biddlecome et al., 1996), offering a negative 
feedback mechanism to control their own activity.
1.2.3. Ca2+ removal
For regulated Ca2+ signaling it is essential that Ca2+ 
can also be rapidly removed from the cytosol. ATP-
driven Ca2+ pumps include plasma membrane Ca2+ 
ATPases (PMCAs), extruding Ca2+, and the SR/
ER Ca2+ ATPases (SERCAs), which underlie the 
sequestration of Ca2+ in the ER/SE (Clapham, 
2007). Ca2+ can also be transported by the plasma 
membrane Na+/Ca2+ exchangers (NCXs), which in 
this ‘normal’ mode utilize the driving force of Na+ 
for Ca2+ extrusion (Clapham, 2007). As NCXs are 
dependent on the electrochemical driving forces 
for Ca2+ and Na+, they can also work in the so-called 
reverse mode, leading to Ca2+ entry when Na+ is 
extruded.
The mitochondrial Ca2+ uniporter can be utilized to 
take in Ca2+ driven by the mitochondrial membrane 
potential (Kirichok et al., 2004). However, 
mitochondria should not act as Ca2+ stores, but Ca2+ 
should be removed upon reduced Ca2+ signaling 
activity. Ca2+ uptake depletes the mitochondrial 
membrane potential, and mitochondria are thus 
one of the targets of Ca2+ toxicity (Szabadkai et al., 
2008).
1.3. G-protein-coupled receptors
The concept of GPCRs is well established (Milligan 
et al., 2006b; Oldham et al., 2008). They represent 
perhaps the largest and most diverse superfamily 
of signaling receptors in the mammalian genome. 
GPCRs (or related molecules) can also be found 
in yeast, plants and invertebrates, indicating they 
originated early in evolution (Kroeze et al., 2003). 
GPCRs are able to respond to various stimuli, 
including light (i.e. photons), Ca2+, biogenic amines, 
odorants, nucleotides, lipids, and proteins, among 
others (Kroeze et al., 2003). The human genome 
contains at least 800 GPCR sequences (Fredriksson 
et al., 2003). GPCRs are also important drug targets. 
It has been estimated that 30% of drugs on the 
market target GPCRs one way or another (Hopkins 
et al., 2002).
GPCRs acquired their name from a relatively small 
cytoplasmic protein complex of three proteins 
termed heterotrimeric G-proteins. These G-proteins 
can associate with the cytoplasmic domain of GPCRs 
and are their ‘signaling partners’. A characteristic 
structural feature of all GPCRs is that they contain 
seven transmembrane α-helices within a single 
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polypeptide chain; hence, GPCRs are often called 
7TM receptors, heptahelical receptors or, figuratively, 
serpentine-like receptors. The single polypeptide 
chain also has small loops outside and inside the 
cell, preceded and followed by the membrane-
spanning α-helices and N-terminal extracellular and 
C-terminal cytoplasmic domains.
1.3.1. Classification of GPCRs 
The classification of GPCRs is complex and several 
parallel systems still exist. In 1994, Kolakowski 
introduced the first systematic nomenclature for 
GPCRs, the A–F classification system (Kolakowski, 
1994). In derivatives of Kolakowski’s system, classes 
A, B, and C are more or less written in stone, but 
on some occasions Frizzled and olfactory receptor 
types are separated into own classes. Kolakowski 
classification is based on sequence similarities, 
disulfide bonds and the presence of key residues. 
Subsequently, the GRAFS nomenclature was 
developed by Fredriksson and coworkers. This is 
based more on presumed phylogenetic criteria and 
includes glutamate, rhodopsin, adhesion, frizzled/
taste2 and secretin families. The major difference 
compared to A–F classification is the separation 
of the adhesion and secretin families from class 
B (Fredriksson et al., 2003). Each classification 
method has certain limitations and is a compromise 
at best. The nomenclature used in this thesis follows 
the GRAFS system.
The rhodopsin family, formerly class A receptors, is 
the largest group in the GRAFS nomenclature and is 
named according to the prototypic photon receptor 
first isolated from bovines in 2000 (Palczewski et 
al., 2000). This is the largest group, with 670 or so 
members (Lagerstrom et al., 2008). The rhodopsin 
family is further divided into four subgroups: α, β, γ 
and δ. The last of these contains all olfactory receptors, 
making it the largest single subgroup of the rhodopsin 
family. The typical structural feature is disulfide 
bridges connecting extracellular loops between 
transmembrane helices I and II. Almost every member 
contains an NSxxNPxxY motif in helix VII and a 
DRY motif facing the cytoplasm in helix III. DRY is 
needed both for structural stabilization and G-protein 
activation. Also typical is a small N-terminal domain 
compared to other GPCR classes. Rhodopsin family 
receptors recognize a vast variety of ligands, from tiny 
photons (with the help of bound 11-cis-retinal) to 
small biogenic amines, lipids, peptides and proteins. 
Endocannabinoid receptors CB1 and CB2 belong to 
this group, as do orexin receptors OX1 and OX2.
Glutamate family receptors were formerly known 
as class C receptors. They consist of metabotropic 
glutamate receptors (eight in humans), 
γ-Aminobutyric acid (GABA) receptors (two 
in humans), the single calcium-sensing receptor 
(CASR) and the taste receptor type 1 (TAS1) 
(Schioth et al., 2005). The typical structural elements 
of these receptors are two N-terminal lobes that 
close together surrounding the ligand, referred to as 
the Venus flytrap according to the common name of 
the carnivorous plant Dionaea muscipula (Schioth et 
al., 2005).
Adhesion family members (another member of 
the former class B) have very long N-terminal 
domains and several modular structures such as 
EGF repeats, leucine-rich repeats and lectin-like and 
immunoglobulin domains that are known to mediate 
protein–protein interactions in adhesion. Indeed, it 
has been shown that the family of adhesion GPCRs 
binds to a wide variety of cellular and extracellular 
matrix targets (Yona et al., 2008). These receptors 
have been indicated in the immune response, 
development and cancer (Yona et al., 2008).
Frizzled receptors have only recently been accepted 
as GPCRs, although they are atypical and not always 
coupled to heterotrimeric G-proteins (Schulte, 
2010). Frizzleds are important during embryonic 
development controlling cell fate, proliferation and 
stem cell differentiation, and receive signals from 
secreted Wnt glycoproteins. In adults, Wnt/Frizzled 
signaling is usually inactive, but is frequently seen to 
be functional in cancer cells (Teglund et al., 2010).
The secretin family is the remaining member of the 
earlier class B (Fredriksson et al., 2003). A hallmark of 
this receptor family is a large extracellular N-terminal 
domain of about 60–80 amino acids and numerous 
cysteins, resulting in stabilizing disulfide bridges 
and thus sharing some structural features with the 
adhesion family (Schioth et al., 2005). Ligands of 
the secretin family of receptors are mainly peptides, 
including secretin, glucagon, and parathyroid 
hormone (Fredriksson et al., 2003).
1.3.1.1. Orphan GPCRs
Orphan GPCRs are receptors lacking defined 
endogenous ligands (Civelli et al., 2006). They are 
usually discovered by molecular biology approaches 
based on sequence similarities, but their ligands 
remain to be elucidated by these techniques (Chung 
et al., 2008). The “deorphanization” of the receptor 
of interest is usually done by a technique known as 
the reverse pharmacology. This is usually carried 
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out by expressing the corresponding receptor in 
eukaryotic cells and screening through a chemical 
library of known and potential ligands for binding 
or signal transduction abilities (Chung et al., 2008). 
This has proven to be a very successful method and 
new high-throughput assays are further speeding up 
the process. It is, however, not known whether all 
orphan GPCRs have endogenous ligands or whether 
the ‘hits’ are physiologically relevant (Civelli et al., 
2006).
1.3.1.2. GPCR oligomerization
In recent years, experimental evidence has 
accumulated suggesting that GRCPs can exist as 
dimers or oligomers. Dimerization can occur between 
identical or structurally related GRCPs, or even 
between members of different classes (Breitwieser, 
2004; Milligan et al., 2006a), and dimerization (or 
oligomerization) is the natural state of many GPCRs 
(Lohse, 2010). The protein–protein interactions 
in complex formation are finally beginning to be 
understood. Interestingly, both covalent and non-
covalent binding have been indicated (Gonzalez-
Maeso, 2011), and TM-I and TM-IV appear to 
be central contact sites. The dynamic scale of the 
complexes is also variable, ranging from seconds 
to almost stable complexes. For the muscarinic M1 
receptor, about 30% of the receptors are in complexes 
at any given time point (Hern et al., 2010). Some 
GPCRs (such as the β2-adrenoceptor and GABAB 
receptor) form dimers during protein synthesis 
within the ER and are internalized as dimers 
(Milligan, 2008). Oligomerization of GPCRs may 
alter their ligand binding, activation, desensitization, 
trafficking, and signaling (Gonzalez-Maeso, 2011) 
in a manner that have both physiological significance 
and an impact on the future drug discovery strategies 
(Milligan, 2008). However, for most receptors 
there is thus far no firm evidence for the effect of 
dimerization on the properties mentioned above.
1.3.2. Heterotrimeric G-proteins
Despite the enormous diversity within the GPCR 
family, there are relatively few G-proteins they 
interact with. These small proteins are cytoplasmic 
peripheral membrane proteins. In humans, 21 
Gα subunits, 6 Gβ subunits and 12 Gγ subunits 
are known (Downes and Gautam, 1999; review 
in Oldham et al., 2008). G-proteins are classified 
according to the Gα subunit and can be further 
divided into four subclasses: Gαs (Fung et al., 1981), 
Gαi (Hildebrandt et al., 1983), Gαq/11 (Strathmann et 
al., 1990), and Gα12/13 (Strathmann and Simon, 1991; 
reviewed in Simon et al., 1991). The typical structure 
of Gα contains two structural units: a GTPase 
domain and a helical domain. The GTPase domain 
is highly conserved and present in every member 
of the G-protein superfamily. This domain has two 
important functions: hydrolysis of bound GTP and 
acting as a binding site for the Gβγ complex and 
GPCRs. The helical domain has six α-helices forming 
a bundle that closes the bound nucleotide in a tight 
pocket like a cover. In order to remain in membranes, 
each Gα is palmitoylated at its N-terminus, and 
some also have myristoyl modification (Oldham et 
al., 2008). Gγ subunits additionally contain lipid 
linkers. They can be farnesylated or geranylated, 
ensuring the membrane association of the complex 
(Dupre et al., 2009). 
1.3.2.1. Gαs family
The story of G-proteins already began in 1958 when 
Sutherland and Rall described enzymatic activity 
producing the cyclic nucleotide cAMP (Sutherland 
et al., 1958). It took about two decades until the 
signal-relaying G-protein was described (Limbird 
et al., 1980; Pfeuffer, 1979). Typical features of 
Gαs family proteins include the ability to stimulate 
adenylyl cyclase (AC) and activation by cholera 
toxin (Oldham et al., 2008). 
1.3.2.2. Gαi family
In some experiments, G-proteins appeared to inhibit 
rather than activate AC; this led to the discovery 
of Gαi subunits from cyc
– S49 cells (Bokoch et al., 
1984; Codina et al., 1984; Hildebrandt et al., 1983). 
A little later, another member was discovered with 
a different structure (Pines et al., 1985). It was 
named Gαo (“o” for other). The subgroup currently 
contains Gαi1, Gαi2, Gαi3, Gαo1, Gαo2, and Gαz. Three 
additional members of this subgroup are specific to 
sensory organs: Gαgust participates in the bitter and 
sweet sensation in gustation, and Gαt1 and Gαt2 in 
phototransduction in the retina. All members except 
Gαz are inactivated by pertussis toxin.
1.3.2.3. Gαq/11 family
Currently, the Gαq/11 family consists of Gαq, Gα11, 
Gα14, and Gα15/Gα16 Gα proteins (Mizuno et al., 
2009; Oldham et al., 2008). GPCRs that connect 
to Gαq/11 (or simply Gq) G-proteins are known for 
their ability to temporarily increase the intracellular 
Ca2+ concentration. Upon receptor activation, 
Gαq/11 activates PLCβ (Taylor et al., 1991) and the 
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subsequently produced IP3 binds to its receptors in 
the smooth ER membrane and opens Ca2+ channels, 
leading to an increase in [Ca2+]i (see section 1.2.2 for 
more detailed discussion on Ca2+ and Gq). Other Gq-
activated downstream signaling components include 
DAG-activated PKC, monomeric G-proteins and 
MAPK (Mizuno et al., 2009). Recently, Gα16 has 
been shown to activate Ras independent of PLCβ 
(Liu et al., 2011).
1.3.2.4. Gα12/13 family
The members of this family are structurally distinct 
compared to other Gα families. Gα12/13 proteins have 
versatile functions. They are especially involved in 
targeting Rho via RhoGEFs (guanine nucleotide 
exchange factors) containing a Gα12/13-RGS (regulator 
of G-protein signaling) homology domain, and 
regulate a wide variety of biological processes such 
as embryonic development, cell growth, migration, 
apoptosis, and neuronal responses (Suzuki et al., 
2009). More than 30 Gα12/13-coupling GPCRs 
are known, including receptors for angiotensin-2, 
serotonin, and lysophosphatidic acid (LPA) (Riobo 
et al., 2005).
1.3.2.5. Gβγ subunits
Originally, the Gβγ complex was thought to be 
unimportant in signal transduction and to merely 
act as a docking site for and a negative regulator of 
Gα (Neer, 1995). Nowadays, Gβγ is also known to 
be a crucial signal transducer (Clapham et al., 1997; 
Dupre et al., 2009). Gβγ forms a functional unit 
that is tightly bound and remains as a heterodimer 
in physiological conditions; the complex only 
dissociates under denaturating conditions (Schmidt 
et al., 1992). In humans there are six Gβ and 12 Gγ 
proteins, but not all possible Gβγ-pairs have been 
detected in vivo. This might be related to incompatible 
structural features of the different subunits or simply 
tissue-specific expression profiles. Nevertheless, 
the existing pool of combinations is impressive and 
seemingly adequate to accomplish the tasks needed 
(Milligan et al., 2006b).
Gβ features a β-propeller secondary structure with 
7 alternating tryptophan-aspartate (WD) repeats 
(Sondek et al., 1996), found in 40 or so distinct 
proteins forming a unique group (Neer et al., 1994; 
Smith et al., 1999). Five β-subunits are known; β1–4 
are very homologous, while β5 is structurally different. 
The overall homology of specific Gβγ orthologs in 
mammals is nearly 100% (Dupre et al., 2009). Gβγ 
has been shown to directly regulate various signaling 
components, including PLCβs (Camps et al., 1992), 
G-protein-coupled inwardly-rectifying potassium 
channels (GIRK) 1 and 2 (Huang et al., 1995), AC 
(Tang et al., 1991), MAPK (Crespo et al., 1994), 
N-type voltage-gated Ca2+ channels (Zamponi et al., 
1997), and Ras (Mattingly et al., 1996).
1.3.2.6. General concept of the GPCR cycle and 
regulation of the signaling 
According to the classical model of the guanine 
nucleotide cycle (Kimple et al., 2011), in the resting 
state the Gαβγ complex is associated with the 
receptor and GDP bound to the Gα subunit. Binding 
of a ligand induces a conformational change in the 
receptor structure that is relayed to the cytoplasmic 
domain. The change in the receptor structure 
enhances the exchange of the bound GDP for the 
abundant GTP in the Gα subunit; the receptor 
functions as a GEF (Oldham et al., 2008). The 
nucleotide exchange leads to the dissociation of the 
trimeric Gαβγ complex from the cytoplasmic part 
of the GPCRs. Gα is further dissociated from Gβγ 
and both are able to diffuse (to some degree) along 
the plasma membrane and activate specific target 
proteins such as AC, PLC, monomeric G-protein 
GEFs, and ion channels (Oldham et al., 2008). 
Regulation of targets ends when the intrinsic GTPase 
activity of the Gα subunit catalyzes the hydrolysis of 
GTP to GDP (Coleman et al., 1994). The subsequent 
conformational change and increased affinity towards 
GPCR and Gβγ then restores the resting complex.
The rate of GTP hydrolysis can be enhanced by RGS 
proteins (Kimple et al., 2011; Ross et al., 2000). These 
proteins function as the GTPase-activating proteins 
(GAPs), and they all contain a hallmark structural 
element, a nine-α-helix bundle (Tesmer et al., 1997). 
Their action has been explained by stabilization of 
the Gα in a transition state and lowering of the free 
energy required for GTP hydrolysis (Tesmer et al., 
1997). Altogether, 37 RGS-domain-bearing proteins 
with variable preferences for Gα subunit families have 
been identified in humans (Kimple et al., 2011).
After agonist-induced activation of GPCR and 
the corresponding intracellular signaling pathway, 
signaling must be down-regulated in order to 
maintain the responsiveness of the cell to new stimuli. 
The built-in GTPase activity of the Gα subunit and 
RGS proteins partly affects the attenuation of the 
signaling cascade, but GPCRs are also controlled 
by membrane trafficking, leading to the rapid 
desensitization of GPCR signaling ( Jean-Alphonse 
et al., 2011). Ligand-induced internalization occurs 
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via clathrin-coated pits (CCP) with the assistance 
of the arrestin family of adaptor proteins (DeWire 
et al., 2007). β-Arrestins 1 and 2 are recruited from 
the cytoplasm by GPCR kinase (GRK)-catalyzed 
phosphorylation of the GPCR. Phosphorylation 
creates a docking site for arrestins, and following 
the binding of β-arrestin to GPCR, uncouples the 
trimeric Gαβγ complex and transiently inactivates 
the receptor. β-Arrestins also guide GPCRs to CCP, 
where the complex is internalized by endocytosis. 
The internalizated receptor then has two potential 
fates: it might be dephosphorylated within the 
endosome and recycled back to the plasma 
membrane, fully capable of binding the ligand again, 
or it may be directed to lysosomes for degradation 
( Jean-Alphonse et al., 2011).
1.4. Orexins and orexin receptors
1.4.1. Overview
1.4.1.1. Discovery of orexins
Orexins are secreted neuropeptides that have 
been known for only a little more than a decade. 
They were found simultaneously in 1998 by two 
independent research groups applying different 
scientific approaches. Yanagisawa and coworkers 
isolated a 33 amino acid (aa) peptide and showed 
that it could activate an orphan receptor, at that time 
termed HFGAN72 (Sakurai et al., 1998). Another 
peptide, 28 aa in length, also activated HFGAN72. 
Subsequently, a second receptor with sequence 
similarity to HFGAN72 was cloned and it responded 
to both peptides as well. A 130 aa precursor peptide 
was shown to encode both 33 aa and 28 aa peptides 
that are cleaved proteolytically into two final 
peptides. These peptides were named orexins (from 
the Greek word for appetite) for their ability to 
induce food intake in satiated rats following injection 
into the lateral ventricle (Sakurai et al., 1998). The 33 
aa peptide was named orexin-A (OxA) and the 28 
aa peptide orexin-B (OxB). Those no-longer-orphan 
receptors became the OX1 and OX2 orexin receptors. 
The precursor peptide was termed prepro-orexin 
(PPO) (Sakurai et al., 1998).
At the same time, the research group of Sutcliffe – 
using directional tag PCR subtraction – showed 
that a certain hypothalamic mRNA species named 
clone 35 was expressed in the lateral hypothalamus. 
Clone 35 encoded a potential secretory peptide 
(containing a signal sequence) of 130 aa in length 
that gave rise to two peptides (de Lecea et al., 1999). 
They named the peptides hypocretins according to 
their site of discovery (hypothalamus) and sequence 
resemblance to the hormone secretin. Hypocretin-1 
is therefore equivalent to orexin-A and hypocretin-2 
to orexin-B. The gene for prepro-orexin is called hcrt. 
The nomenclature varies between publications, but 
this thesis follows the orexin nomenclature proposed 
by Sakurai et al.
Mammalian (at least canine, human, murine and 
porcine) prepro-orexin is constructed of 130–131 
amino acids. Human prepro-orexin is located on 
chromosome 17, more precisely in position 17q21 
(Sakurai et al., 1999). The gene contains two exons: 
5’-UTR (untranslated region) and 7 aa of the signal 
sequence are located in the first exon and the rest of 
the signal sequence and both orexin-A and orexin-B 
sequences in exon 2.
1.4.1.2. Orexin-A and orexin-B
OxA consists of 33 amino acids and two intrachain 
disulfide bridges, between cysteins 6 and 12 and 
between 7 and 14, respectively. The N-terminal 
glutamine of OxA is post-translationally modified 
to a pyroglutamyl residue, while the C-terminal end 
is amidated (Sakurai et al., 1998). OxA amino acid 
sequences are identical in humans, mice, rats, dogs, 
and pigs (Kukkonen et al., 2002). OxB is a 28 amino 
acid linear peptide that shares an identical seven 
amino acid segment with secretin. The C-terminal 
part of OxA and OxB is relatively similar, including 
the post-translational amidation; the overall 
sequence homology between OxA and OxB is 46% 
(Figure 1.) (Sakurai et al., 1998).
The three-dimensional structures of orexin-A and -B 
have been resolved. They are both constructed of two 
α-helices at an angle of approximately 70 degrees to 
each other (Kim et al., 2004; Lee et al., 1999), and 
the overall 3D structures are quite similar, explaining 
their ability to bind the same receptors (Kim et al., 
2004). OxA is able to penetrate the blood–brain 
barrier, whereas OxB is not. This is probably caused 
by the higher lipophilicity of OxA and the shorter 
plasma half-life of OxB (Kastin et al., 1999). The 
physiological significance of this is not known.
1.4.1.3. Orexin receptors
Orexin receptors belong to the GPCR superfamily 
and more specifically to the rhodopsin family in the 
GRAFS classification. OX1 contains 425 amino acids 
and the sequence homology between humans and 
rats is 91–98% (Sakurai et al., 1998). OX2R is slightly 
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larger, with 444 aa. The aa sequence similarity 
between OX1 and OX2 is about 64% (Sakurai et 
al., 1998). Both receptors are likely to couple to 
G-proteins of the families Gi, Gs, and Gq (Holmqvist 
et al., 2005; Randeva et al., 2001) (Figure 2.). Studies 
on the expression systems have suggested that OX2R 
has a rather equal affinity for OxA and OxB, while 
OX1R shows a ten-fold higher affinity/potency for 
OxA (Sakurai et al., 1998), although this is greatly 
dependent on the expression system (Putula et al., 
2011).
1.4.1.4. Expression and tissue distribution of 
orexins and orexin receptors
Orexins are produced by orexinergic (OX) neurons, 
a relatively small population of neuronal cells 
located in the hypothalamus, especially in the lateral 
hypothalamic area (LHA), posterior hypothalamus 
(PH), and perifornical area (PF) (de Lecea et al., 
1998; Peyron et al., 1998; Sakurai et al., 1998). It 
has been estimated that in human brains there are 
approximately 70 000 orexinergic neurons (Peyron 
et al., 1998). In rat brains the number is roughly 3000 
(Nambu et al., 1999). Despite the small number of 
OX neurons, they send projections to many brain 
areas (Figure 3.), suggesting that orexins modulate 
multiple systems (Kirchgessner, 2002). The most 
notable innervation targets include some other areas 
of the hypothalamus, the olfactory bulb, cerebral 
cortex, thalamus, brainstem, and spinal cord (Date 
et al., 1999; Mondal et al., 1999; Peyron et al., 1998; 
Sutcliffe et al., 2000; van den Pol, 1999; Willie et 
al., 2001). Within the hypothalamus, OX neurons 
project to the arcuate nucleus and form synapses to 
cells containing neuropeptide Y (NPY) (Date et al., 
1999; Horvath et al., 1999a; Peyron et al., 1998). The 
close proximity of NPY neurons and OX neurons 
has also been shown to occur in the hypothalamic 
paraventricular nucleus (Broberger et al., 1998; 
Horvath et al., 1999a). This is very interesting, 
since NPY is a known orexinergic peptide (Kalra et 
al., 1991), so it is possible that orexin, in part, acts 
through NPY when stimulating feeding. 
The expression of orexin receptors is convergent 
with that of OX neurons. However, there is a notable 
difference in expression patterns between OX1R and 
OX2R (Marcus et al., 2001). OX1R mRNA is found 
in the ventromedial hypothalamic nucleus (VMH) 
and anterior part of the hypothalamus near the 
suprachiasmatic nucleus (Trivedi et al., 1998). OX1R 
is also expressed in the hippocampal CA1 and CA2 
areas, in the raphe nuclei, and the locus coeruleus 
(Marcus et al., 2001). Hypothalamic expression 
of OX2R is mostly found in the tuberomammilary 
nucleus, LHA, PVN, and arcuate nucleus, and 
outside hypothalamus, especially in the amygdala, 
bed nucleus of the stria terminalis, and nucleus 
accumbens (Marcus et al., 2001; Trivedi et al., 
1998).
Orexins and orexin receptors are also expressed 
in peripheral tissues, although the origin of orexin 
in peripheral tissue is not completely understood 
(Heinonen et al., 2008). Orexins are suggested to be 
Figure 1. A) Schematic structure of the prepro-orexin. B) Orexin A contains two disulphide bridges in contrast 
to linear orexin B. C) The C-terminal aa sequences of both peptides are very homologous.
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found in vagal afferent neurons, the gastrointestinal 
tract and surrounding enteric nervous system (ENS), 
pancreas, adrenal gland, kidney, testis and ovary, 
lung, heart, thyroid gland, and both brown and white 
adipose tissue (Heinonen et al., 2008; Kirchgessner, 
2002).
1.4.2. Orexin receptor signaling to the cell 
interior
1.4.2.1. Increase in intracellular calcium levels
One of the first measured responses to orexin 
receptor challenge ever recorded was an increase 
in [Ca2+]i (Sakurai et al., 1998). Subsequently, the 
Ca2+ response has been described in several cell 
lines, including CHO-K1 (Lund et al., 2000), PC12 
(Holmqvist et al., 2002), Neuro-2A (Holmqvist et 
al., 2002), and HEK-293 (Magga et al., 2006), as well 
as in cultured neurons from the hypothalamus and 
dorsal root ganglia (Eriksson et al., 2001; van den Pol 
et al., 1998). In recombinant CHO-hOX1 cells, the 
source of Ca2+ seems to differ according to the OxA 
concentration. At lower concentration Ca2+ entry is 
independent of PLC activity, indicating a receptor-
operated Ca2+ entry pathway (Ekholm et al., 2007; 
Kukkonen et al., 2001; Larsson et al., 2005; Lund 
et al., 2000). This pathway is able to promote the 
activation of PLC-dependent IP3 production, Ca
2+ 
release and further entry via SOC (Kukkonen et al., 
2001; Larsson et al., 2005; Lund et al., 2000). Higher 
concentrations of orexins activate the PLC response 
directly without any ROC activity (Kukkonen et al., 
2001; Lund et al., 2000). The identity of the ROC 
is not fully verified, but likely candidates are TRPC 
channels (Nasman et al., 2006; Peltonen et al., 
2009).
1.4.2.2. Activation of adenylyl cyclase
The family of ACs consists of nine membrane-
bound isoforms and one soluble isoform. ACs 
are divided into four main groups: group 1 (AC1, 
AC3, and AC8), group 2 (AC2, AC4, and AC7), 
group 3 (AC5 and AC6), and group 4 (AC9). The 
soluble isoform forms a group of its own (Patel et 
al., 2001). All membrane-bound AC isoforms are 
regulated by Gs. Group 1 enzymes are Ca
2+-sensitive. 
Group 2 and 3 enzymes respond to PKC and Gβγ. 
All isoforms except AC9 are activated by alkaloid 
forskolin. Activation of ACs leads to the production 
of cAMP and activation of protein kinase A (PKA), 
cAMP-regulated ion channels, and EPAC (GEF 
for Rap1) (Patel et al., 2001). Stimulation of both 
orexin receptors has been shown to activate AC 
and cAMP production in recombinant cell lines 
(Holmqvist et al., 2005; Tang et al., 2008) and native 
cells (Gorojankina et al., 2007; Malendowicz et al., 
1999). Coupling of OX1 to AC in the CHO-hOX1 
expression system appears to be a complex process. In 
addition to direct Gs activation, a novel PKC isoform, 
PKCδ, is involved in AC activation, while Ca2+ has 
a permissive role in the activation (Holmqvist et 
al., 2005). OX1 is also able to inhibit AC via Gi-
coupling (Holmqvist et al., 2005). Conversely, there 
have been studies in which no AC regulation has 
been seen (Larsson et al., 2003; Magga et al., 2006; 
van den Pol et al., 1998). This discrepancy might 
Figure 2. Schematic structure of OX1 and OX2 orexin receptors on the plasma membrane and the G-proteins 
they couple.
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reflect either methodological issues or differences 
in cell line/tissue-specific isoform expression and 
activation profiles, or the subcellular localization 
of various AC isoforms (Ostrom et al., 2012). In 
addition, the heart-specific isoform AC6 seems to 
participate in signaling without cAMP production 
(Gao et al., 2011); therefore, cAMP measurement 
may not always reflect AC activation.
1.4.2.3. Activation of protein kinases by OX1
The kinase cascades initiated by OxA binding to OX1 
are complex and the underlying signaling pathways 
affect each other. The activation of PLCβ leads to the 
production of DAG and concomitant activation of 
PKC. Holmqvist et al. (2005) identified the PKCδ 
isoform to be the target of OX1, and similar results 
were seen in other studies ( Jäntti et al., 2011). 
The MAP kinase family consists of four members, 
ERK1/2, JNK, ERK5 and p38. The common feature 
of these kinases is their activation by cascade-like 
phosphorylation. OX1 challenge leads to ERK1/2 
and p38 kinase phosphorylation (Ammoun et 
al., 2006a; Ammoun et al., 2006b). Downstream 
effectors contributing to ERK1/2 activation include 
at least Ca2+ influx, PLC/PKC, Ras, Src, and PI3K 
(Ammoun et al., 2006a). Similar results have been 
recorded with the OX2 expression system (Tang 
et al., 2008). MAP kinases regulate several cellular 
processes, including proliferation and apoptosis. 
Interestingly, OxA-induced apoptosis is regulated by 
p38 MAPK acting independently of Ca2+ influx, p53, 
and caspases (Ammoun et al., 2006b).
1.4.2.4. Activation of phospholipases by OX1
Phospholipases are enzymes that hydrolyze 
glycerophospholipids (Murakami et al., 2011). Their 
nomenclature originates from enzymatic specificity. 
PLA1 releases fatty acid bound to the sn1 position in 
the glycerol backbone, while PLA2 is more specific 
towards the sn2 position. An enzyme having both 
of the aforementioned activities may be termed 
PLB. PLC cleaves phospholipids releasing DAG 
and the head group along with the sn3 phosphate, 
and finally PLD releases phosphatidic acid (PA) 
and the head group without the sn3 phosphate 
(Figure 4.). Phospholipases might also be selective 
to phospholipid species or fatty acids bound to the 
glycerol backbone (Murakami et al., 2011).
Figure 3. Summary of the organization of the orexin neuronal system in sagittal section of rat brain. The 
OX neurons (indicated as rasterized spheres) are located solely in the hypothalamus, but they send axonal 
projections to many brain areas (black arrows). The strongest projections go to the brain stem. (LC, locus 
coeruleus; TMN, tuberomammilary nucleus.) Picture is adapted from Ohno K and Sakurai T, 2008.
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1.4.2.4.1. Phospholipase A2
1.4.2.4.1.1. Overview
Our knowledge of phospholipase A2 (PLA2) has 
increased tremendously within the last two decades. 
PLA2s are a relatively large and versatile family 
of lipid-hydrolyzing enzymes sharing common 
specificity towards the sn2 position of the glycerol 
backbone in phospholipids, a position often occupied 
by arachidonic acid or other polyunsaturated fatty 
acids. The released arachidonic acid can then act 
as a precursor for eicosanoid or endocannabinoid 
biosynthesis, while the remaining 2-lysophospholipid 
has signaling functions itself (Murakami et al., 2011). 
PLA2s have several important functions in many 
pathological processes, which has raised huge interest 
among pharmaceutical companies in developing 
specific inhibitors against different members of this 
superfamily (Burke et al., 2009). 
The first PLA2s were discovered from various animal 
venoms (snakes, bee), the first already in 1890. 
The nomenclature is somewhat obscure and owes 
its origin to the classification of old and new world 
snake lipases (group I and group II), and group III 
came along with the discovery of the unique PLA2 of 
bee venom. The discovery of intracellular PLA2 made 
a systematic nomenclature essential (Schaloske et al., 
2006). To date, at least 30 different PLA2 are known 
in mammals. Based on their structure, catalytic 
mechanism and localization, PLA2s are categorized 
into six classes, most of which contain several 
isoforms (Murakami et al., 2011).
1.4.2.4.1.2. Secretory PLA2 family 
PLA2s derived from animal venoms are currently 
known as group I or secretory PLA2 (sPLA2). 
This group contains ten members, which all are 
low molecular weight proteins around 13–15 
kDa (Murakami et al., 2011), with the exception 
of the mammalian enzyme with a size about 55 
kDa (Valentin et al., 2000). The sPLA2 family is 
evolutionarily old and also present in plants (reviewed 
in Lee et al., 2005) and lower animals, including 
insects (Ryu et al., 2003), mollusks (McIntosh et 
al., 1995), and reptiles (Kini, 2003). They have a 
requirement for Ca2+ and they all utilize a similar 
catalytic strategy (His/Asp-dyad and nucleophilic 
attack) of bond cleavage from the sn2 position (Scott 
et al., 1990). Besides being central components in 
animal-derived venoms, sPLA2s participate in many 
physiological processes. Interestingly, a receptor 
for group IB sPLA2 has been discovered (reviewed 
by Hanasaki et al., 2002). PLA2-R is a type 1 
glycosylated membrane protein. Its large N-terminal 
portion contains a fibronectin-like type II domain 
and various carbohydrate recognition domains 
(CDRs). Structurally, it is related to C-type lectins, 
but it has no close homologs in the mammalian 
genome (Higashino et al., 1994).
1.4.2.4.1.3. Cytoplasmic PLA2s or GIVAs 
Cytoplasmic PLA2s or cPLA2s (group IV A or GIVA) 
have six members, including the prototypic cPLA2α. 
Other members include PLA2β, PLA2γ, PLA2δ, 
PLA2ε, and PLA2ζ (these are occasionally referred 
to as IVA–F, respectively). From an evolutionary 
perspective, cPLA2s are relatively new and appeared 
alongside vertebrate evolution and the development 
of eicosanoid signaling (Murakami et al., 2011). 
Cytoplasmic PLA2s belong to the serine hydrolase 
family featuring a catalytic Ser/Asp-dyad at the 
bottom of a funnel-like structure in the catalytic 
domain, as indicated in the crystal structure (Dessen 
et al., 1999). Typical for the serine hydrolase family 
are multiple enzymatic activities, including PLA1, 
PLA2, lysophospholipase and acyltransferase 
activities (Murakami et al., 2011). All members 
(except cPLA2γ) of the cPLA2 family have a C2 
domain in their N-terminus that directs the enzyme 
to the plasma membrane in a Ca2+-dependent 
manner. The only member showing specificity 
towards arachidonic acid is cPLA2α.
1.4.2.4.1.3.1. Regulation of cPLA2α activation
The activation mechanism of cPLA2α is quite well 
known. Increasing [Ca2+]i leads to cPLA2 translocation 
Figure 4. The cleavage sites of phospholipid by common 
phospholipases. The enzymes are indicated in grey 
color.
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to membranes within seconds. Interestingly, the 
target membranes are the intracellular (perinuclear) 
membranes (ER and Golgi) rather than the plasma 
membrane. The explanation lies in the C2 domain 
structure of cPLA2 and different lipid composition of 
the organelle membranes. The C2 domain of cPLA2 
binds to PC, unlike the C2 domain in PKC, which 
prefers phospaditylserine. This has been verified in 
a clever study in which the C2 domains of cPLA2α 
and PKCα were switched (Stahelin et al., 2003). 
Translocation profiles changed accordingly, and 
the chimeric cPLA2α with C2-PKCα shifted to the 
plasma membrane, while PKCα with C2-PLA2α 
moved to the perinuclear membrane. Translocation 
to the perinuclear membrane brings cPLA2 close to 
COX enzymes; indeed, prostaglandin metabolism 
in cPLA2α containing C2-PKCα is diminished 
(Murakami et al., 2003). Interestingly, both chimeric 
cPLA2α and the wild-type enzyme showed a similar 
AA-releasing potential (Murakami et al., 2003). The 
enzyme is further activated by phosphorylation of 
Ser505 by MAPK (Lin et al., 1993). This induces a 
change in the conformation of the protein, revealing 
hydrophobic residues that promote the interactions of 
the catalytic domain with the membrane, even when 
[Ca2+]i has declined. MAPK also phosphorylates 
Ser727 in the C-terminal part of the enzyme. This 
phosphorylation masks the binding site for the 
regulatory protein complex of p11 and annexin A2 
that binds to unphosphorylated Ser727 and prevents 
membrane interactions and enzyme translocation 
(Hefner et al., 2000; Tian et al., 2008). cPLA2α has 
a putative lysine-rich binding site for PIP2; this lipid 
is an important activator of the enzyme (Tucker et 
al., 2009).
1.4.2.4.1.3.2. cPLA2s in health and disease
The generation of a cPLA2α knockout mouse model 
(Pla2g4a–/–) (Uozumi et al., 1997) has increased 
our knowledge of the biological roles of cPLA2α. 
Pla2g4a–/– mice show reduced eicosanoid signaling 
and impairments in immunity (Murakami et al., 
2011). Interestingly, Pla2g4a–/– mice seem less prone 
to many pathological conditions caused by immune 
system malfunctions. Pla2g4a–/– mice show generally 
reduced symptoms in airway anaphylactic responses 
(Uozumi et al., 1997), beomycin-induced pulmonary 
fibrosis (Nagase et al., 2002), the ARDS (adult 
respiratory distress syndrome) model (Nagase et 
al., 2000), rheumatoid arthritis (Hegen et al., 2003), 
and EAE (experimental autoimmune encephalitis), 
an animal model of multiple sclerosis (Marusic et 
al., 2005), indicating an active role for cPLA2α in 
all these pathophysiological processes. In addition, 
involvement of cPLA2α has been indicated in lung 
and prostate cancers (Patel et al., 2008; Weiser-Evans 
et al., 2009), the onset of labor, fertility, and ovulation 
(Uozumi et al., 1997). Recently, a new potential 
function of cPLA2 in Golgi trafficking has been 
proposed (San Pietro et al., 2009). Vesicle-directed 
proteins transfer from the rough ER (rER) to the 
Golgi apparatus for further maturation and vesicle 
packing, and this involves intracisternal connections. 
Wedge-shaped phospholipids created by cPLA2 
activity help to form the positive curvature needed 
in tubule formation. Indeed, various methods to 
inhibit cPLA2 (siRNA, pharmacological inhibitors, 
dominant-negative constructs) block intracisternal 
trafficking in the Golgi apparatus, but do not inhibit 
ER-to-Golgi, Golgi-to-ER or trans-golgi network 
(TGN)-to-plasma membrane transport (San Pietro 
et al., 2009).
1.4.2.4.1.3.3. Other members of the GIVA family    
Much less is known about the remaining members 
of the GIVA family. cPLA2β features an additional 
JimC-domain, making it larger than other family 
members. It possesses an approximately 1500 
times higher lysophospholipase activity than PLA2 
activity. It is constitutively located on mitochondrial 
membranes. Ubiquitously expressed cPLA2γ is an 
unusual GIVA family member, since it lacks the 
characteristic C2-domain (Underwood et al., 1998). 
Membrane remodeling and homeostasis are believed 
to be the main cellular functions of cPLA2γ due to 
prominent lysophospholipase and transacetylase 
activities (Yamashita et al., 2009). cPLA2δ shows 
both PLA1 and PLA2 activities and it translocates 
to perinuclear membranes, but with much slower 
kinetics than c PLA2α (Ohto et al., 2005). cPLA2ε 
and cPLA2ζ are found in the thyroid and ε also in 
muscle and the heart (Ohto et al., 2005). cPLA2ε has 
weak enzymatic activity, but cPLA2ζ has been shown 
to release AA or OA and to show some selectivity for 
PE over PC (Ghosh et al., 2007).
Ca2+-independent intracellular PLA2s are known 
as iPLA2s, group VI or patatin-like phospholipase 
domain-containing lipases (PNPLAs). They are 
the third subgroup and the second largest with 
nine members (PNPLA1–9). Their physiological 
functions vary from membrane homeostasis and 
energy metabolism to signaling (reviewed by 
Murakami et al., 2011). The best characterized 
member of this family is GVIA PLA2β (Balboa 
et al., 1997). Several splice variants of iPLA2β 
are known, but only two are active in vivo. The 
structural hallmark of iPLA2β is the eight ankyrin 
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repeats in the N-terminus (Larsson et al., 1998), 
indicating potential oligomerization. A putative 
binding site for calmodulin is located near the 
C-terminus ( Jenkins et al., 2001). iPLA2β shares a 
similar catalytic mechanism with cPLA2α, but does 
not display any specificity towards arachidonic acid 
in the sn2 position or for the phospoholipid head 
group (Balsinde et al., 2005). This versatile enzyme 
also posses transacetylase and lysophospholipase 
activities (Winstead et al., 2000). iPLA2β involvement 
is indicated in the regulation of monocyte migration 
(Mishra et al., 2008), apoptosis (Atsumi et al., 2000), 
ovarian cancer (Li et al., 2010), and cardiac ischemia 
(McHowat et al., 1998). 
The remaining three subgroups are platelet-
activating factor acetylhydrolase (PAF-AH), also 
known as lipoprotein-associated PLA2, with four 
members (Tellis et al., 2009), lysosomal PLA2s 
(Kim et al., 2004) with two members, and the 
recently discovered adipose-specific PLA2 (Duncan 
et al., 2008). They have been shown to regulate 
various physiological processes, including neuronal 
migration during development (Manya et al., 1998), 
surfactant metabolism (Shayman et al., 2011), and 
adipocyte lipolysis (Duncan et al., 2008).
For a long time, inhibitors of PLA2s have been 
substrate analogues such as MAFP (methoxy 
arachidonyl fluorophosphonate) or ETYA (5,8,11,14-
eicosatetraynoic acid). The use of such inhibitors is 
problematic because of the nonspecific inhibition of 
almost all arachidonic acid-metabolizing enzymes. 
The recent development of more specific and even 
subgroup-selective inhibitors has markedly changed 
PLA2 research. One of the first commercially available 
cPLA2-specific inhibitors was pyrrophenone (Ono et 
al., 2002), which was also used in this thesis (Paper 
II).
1.4.2.4.2. Activation of other phospholipases by 
OX1
Activation of the PLC family has already been 
discussed in section 1.2.2. Briefly, orexins/orexin 
receptors induce the activation of PLC and 
production of the second messengers DAG and IP3 
from PIP2. This leads to the activation of PKC and an 
increase in [Ca2+]i.
OX1 are able to activate yet another lipase, 
phospholipase D (PLD), which hydrolyzes PC to 
PA and choline. Two mammalian PLDs have been 
described, PLD1 and PLD2, each having two splice 
variants that are denoted with the letters a and b 
(PLD1a, PLD1b, PLD2a and PLD2b) (Colley et 
al., 1997a; Colley et al., 1997b; Hammond et al., 
1997; Steed et al., 1998). Both enzymes are initially 
activated by GPCRs, and other regulators include 
phosphoinositides (especially PIP2), Arf and Rho 
GTPases, and phosphorylation by PKC and MAPKs 
(Hammond et al., 1997; Jenkins et al., 2005; Muthalif 
et al., 2000). PLD activation, however, does not 
necessarily require PLC activation (Balboa et al., 
1998; Jäntti et al., 2011). PA, the main product of PLD 
activation, is an intracellular signaling molecule that 
can regulate proteins such as phosphaditylinositol-4-
phosphate 5-kinase (PIP5K) (Moritz et al., 1992), 
mTOR (Fang et al., 2001), Raf (Ghosh et al., 2003), 
and protein phosphatase-1γ ( Jones et al., 2002). 
PLD might partly activate itself: PA activates PIP5K, 
which in turn produces more PIP2 (an activator of 
PLD), creating a possible feed-forward loop. PA 
can be converted to DAG by phosphatidic acid 
phosphohydrolases (Carman et al., 2006; Sciorra et 
al., 1999) or to LPA by PLA1, sPLA2, or autotaxin/
lyso-PLD (reviewed in Mills et al., 2003). LPA can 
act as a GPCR ligand and regulate various biological 
roles, ranging from cell proliferation to wound 
healing and the reversal of differentiation (Mills et 
al., 2003).
OX1 coupling to PLD in CHO cells was first suggested 
in 2008 based on indirect evidence ( Johansson et al., 
2008), and later confirmed in detail by our group 
( Jäntti et al., 2011). Based on the pharmacological 
evidence, the activated isoform is PLD1. A novel 
PKC, probably PKCδ, is required to activate PLD1 
in this cascade ( Jäntti et al., 2011).
1.4.2.5. Signaling through arachidonic acid and 
ARC channels
Arachidonic acid (AA) is a 20-carbon, polyunsaturated 
fatty acid (PUFA). It is not considered as an essential 
fatty acid for humans as such, but its precursor, 
linoleic acid, is, meaning that human metabolism 
cannot produce linoleic acid de novo and therefore 
we must acquire linoleic acid from the diet. There 
are, however, some mammalian species that lack 
the enzymatic machinery to convert linoleic acid 
to AA. AA is best known for its role as a precursor 
in eicosanoid biosynthesis. AA has subsequently 
been shown to be important for endocannabinoid 
biosynthesis (Piomelli, 2003) and to act as such in 
signal transduction, activating certain isoforms of 
PKC (i.e. PKCα) (Lopez-Nicolas et al., 2006), PIK3 
(Hughes-Fulford et al., 2006), and the heat shock 
protein response ( Jurivich et al., 1994). Activation of 
OX1 induces robust release of the AA (Papers I–IV) 
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by cPLA2 activity (Paper II). AA release is dependent 
on the Ca2+ influx and possibly the activation of 
MAPK (Paper I).
The idea that AA itself might regulate Ca2+ currents 
came from the studies of Shuttleworth and coworkers 
(Shuttleworth et al., 1998) on the HEK293 cell line 
and muscarinic receptors. They showed that AA was 
able to activate Ca2+ entry without any apparent 
PLC activation. The electrophysiological properties 
of the measured Ca2+ conductance also suggested a 
distinct channel population. Within a decade, the 
concept of AA-regulated Ca2+ conductance channels 
(ARC channels) had been established. ARC is a 
Ca2+-selective, low conductance channel acting in a 
store-independent manner in the plasma membrane. 
The ARC channel has recently been suggested to 
consist of three Orai1 and two Orai3 proteins (but 
not Orai2) in a pentameric assembly (Mignen et al., 
2009).
1.4.3. Physiological effect of orexins
1.4.3.1. Regulation of metabolism
The tissue expression profile of orexins and orexin 
receptors probably reflects their biological role. At 
the time of their discovery, it was suggested that 
orexins act as regulators of feeding (Sakurai et al., 
1998). This finding was supported by the fact that 
orexins and orexin receptors are found in many brain 
areas related to feeding, reward and direct neuronal 
regulation of the gastrointestinal tract (GIT). They 
are also present in peripheral tissues related to 
feeding and metabolic regulation (GIT and ENS, 
the pancreas, adipose tissue and adrenal and thyroid 
glands). PPO mRNA levels are upregulated in fasting 
(Sakurai et al., 1998). Interestingly, similar regulation 
is also seen in the flatfish, Verasper moseri (Amiya et 
al., 2012), possibly indicating an evolutionarily old 
mechanism of metabolic regulation. OX neurons 
are able to respond to various metabolic signals 
originating from the periphery (Tsuneki et al., 2012). 
These include glucose, leptin, and grehlin (Moriguchi 
et al., 1999; Yamanaka et al., 2003). OX neurons also 
respond to amino acids (aa) that revert the inhibitory 
effect of glucose on these neurons (Karnani et al., 
2011). The stimulation of OX neurons is dependent 
on nonessential aa. Previously, only essential aa have 
been shown to set off neuronal activation (Blouet et 
al., 2009; Hao et al., 2005). In certain physiological 
conditions, the ability to detect nonessential aa is 
beneficial. Nonessential aa more readily cross the 
blood–brain barrier than essential aa (Oldendorf et 
al., 1976). Altered concentration ratios of essential 
and non-essential aa in the brain could therefore 
indicate deficiency of essential aa in the blood. This 
might relate to an inadequate dietary composition or 
an overall increase in aa in the blood due to muscle 
protein catabolism during prolonged starvation. The 
ability of OX neurons to sense differences in aa levels 
might function as a feedback mechanism to induce 
feeding as a response to a deficiency of aa (Karnani 
et al., 2011). Centrally, but not intraperitoneally 
administrated antibodies against orexin peptides 
directly reduced food intake, pointing to the role of 
endogenous orexins in feeding (Yamada et al., 2000). 
Recently, Okamura and Takakusaki presented a 
trigger role for OxA in the regulation of the cephalic 
phase of feeding, including anticipatory secretion 
priming the gut to digestion (Okumura et al., 2008). 
Their theory is a synthesis of several details including 
localization of OX neurons in the LH and the long-
known role of LH in the regulation of feeding, 
including gastric acid secretion (Tache et al., 1990).
OxA has been shown to directly stimulate gastric 
acid secretion when administrated centrally, while 
intraperitoneal injection fails to induce secretion 
(Takahashi et al., 1999). OxA appears to be a specific 
brain-derived gastric acid secretion-stimulating 
substance, because many tested chemicals or 
peptides are ineffective or inhibitory (Okumura 
et al., 1994; Okumura et al., 1990; Okumura et al., 
1991; Okumura et al., 2000). The stimulatory action 
of OxA is relayed by the vagal system, since atropine 
or vagetomy completely blocks the secretion 
(Takahashi et al., 1999). The dorsal motor nucleus of 
the vagus (DMV) contains orexin-immunoreactive 
nerve terminals and also OX1 receptors, and GIT-
projecting neurons of the DMV are directly activated 
by OxA to produce gastric secretion and motility 
(Grabauskas et al., 2003; Krowicki et al., 2002). 
Orexins also affect pancreatic exocrine secretion, 
an important part of the cephalic phase response, 
in a vagus-dependent manner (Miyasaka et al., 
2002). Hypoglycemia has been shown to stimulate 
OX neurons (Briski et al., 2001; Cai et al., 2001). 
Injection of the OX1 antagonist SB334867 into the 
DMV has been shown to block insulin-induced 
hypoglycemia stimulation of pancreatic nerve firing, 
while injection of OxA increased firing 30-fold (Wu 
et al., 2004). These findings support the idea of OxA 
acting as a trigger molecule in the cephalic phase of 
feeding, which not only activates the secretion but 
also the motility of the gut. Interestingly, central 
administration of OxA also induces feeding-related 
behavior, such as grooming and burrowing (Ida et al., 
1999).
Orexins also have a regulatory role in pancreatic 
endocrine section. Based on immunohistochemical 
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analysis, Quedraogo and coworkers suggested the 
presence of OxA and OX1 in pancreatic α- and β-cells 
(Ouedraogo et al., 2003). OxA has been shown 
to inhibit glucagon secretion by down-regulating 
preproglucagon via Ca2+ and the transcription factors 
CREB and Foxo-1 (Goncz et al., 2008).
Very recently, an interesting and new role for 
orexins in the regulation of brown adipose tissue 
(BAT) development has been described (Sellayah 
et al., 2011; Tupone et al., 2011). It has been 
shown that orexin signaling is needed to initiate 
the neonatal BAT developmental program. PPO-
null mice demonstrated striking differences in BAT 
morphology, which is the most likely reason why 
these mice may develop obesity.
1.4.3.2. Regulation of sleep/wakefulness and 
arousal
Furthermore, orexins/receptors are found in brain 
areas known to control the sleep/wake cycle and 
arousal (Adamantidis et al., 2007; Sakurai et al., 
2010). The effect of orexins on feeding might 
be indirect, for instance with increased arousal 
resulting in more efficient food search/feeding, since 
prolonged OxA treatment does not increase food 
intake or body weight in the same way, for example, 
as NPY. Orexins have been shown to affect both 
slow-wave and REM (rapid eye movement) sleep. 
Several studies have suggested that the promotion of 
wakefulness by orexin occurs via the stimulation of 
histamine-producing neurons of the hypothalamic 
tuberomammilary nucleus (TMN) (Bayer et al., 
2001; Eriksson et al., 2001), noradrenergic neurons 
of the locus coeruleus (LC) (Hagan et al., 1999), and 
cholinergic laterodorsal tegmental neurons (Burlet 
et al., 2002). Noradrenergic neurons fire rapidly 
during wakefulness, reduce firing during NREM 
sleep, and fall into almost total silence during REM 
sleep. On the contrary, GABA/galaninergic neurons 
of the hypothalamic ventrolateral preoptic nucleus 
(VLPO) are active during sleep. These neurons 
reciprocally inhibit each other and maintain the states 
of wakefulness and sleep. OX neurons send dense 
projections to the aforementioned monoaminergic 
nuclei (Nambu et al., 1999; Peyron et al., 1998), 
and orexins have been shown to increase the firing 
of noradrenergic neurons of the LC (Horvath et al., 
1999b), dorsal raphe nucleus (Brown et al., 2001), 
and TMN (Eriksson et al., 2001). In general, orexin 
neurons are fully active during active wakefulness 
and remain almost silent during sleep (Sakurai et al., 
2010). OX neurons, monoaminergic/cholinergic 
neurons in the brain stem waking center, and 
GABAergic neurons in the VLPO are connected 
to each other in a triangular manner: OX neurons 
send excitatory projections to monoaminergic 
neurons, which in turn send inhibitory projections 
back to the OX neurons (Figure 5.). VLPO sleep-
promoting neurons inhibit both OX neurons and 
monoaminergic neurons (Sakurai, 2007). During 
arousal, VLPO and monoaminergic neurons inhibit 
each other, while OX neurons stabilize the waking 
state by enhancing signaling in the wake center 
(Sakurai, 2007). Recently, (Yamanaka et al., 2010) 
described a positive feedback loop of orexin-activated 
OX neurons. They showed that OX neurons project 
to themselves and are able to activate themselves 
both directly and indirectly (via increased excitatory 
input from orexin-activated glutaminergic neurons) 
through OX2. They proposed that this mechanism 
might function to maintain the activity of OX neurons 
during wakefulness (Yamanaka et al., 2010).
1.4.3.3. Orexins in narcolepsy
Narcolepsy is a chronic neurological condition 
or disorder characterized by excessive daytime 
sleepiness and falling asleep at inappropriate 
moments and situations (sleep attacks), and also by 
a reduced onset of REM sleep (Ohno et al., 2008). 
Night-time sleep is often fragmented and associated 
with hypnagogic hallucinations prior to falling 
asleep and sleep paralysis in awakening (Ohno et 
al., 2008). Narcoleptic patients often suffer from 
cataplexy, a sudden weakening of the muscle tone. 
Cataplexy attacks are usually set off by emotional 
stimuli, and the degree of attacks ranges from minor 
jaw-dropping to a complete collapse of the postural 
muscles (Sakurai et al., 2010).
The clue that orexins and orexin receptors are involved 
in narcolepsy came from animal studies. Dogs have 
a genetic mutation destroying the functionality of 
OX2R (Lin et al., 1999). The phenotype resembles 
that of human narcoleptic patients. Likewise, PPO 
gene knockout mice show narcoleptic symptoms 
(Chemelli et al., 1999), as do mice models in which 
OX neurons are genetically destroyed (Hara et 
al., 2001). Cerebrospinal fluid (CSF) samples are 
virtually devoid of OxA in approximately 95% of 
human narcoleptics with cataplexy (Nishino et al., 
2000). Taken together, these data indicate that the 
lack of either orexins or OX2 results in a narcoleptic 
phenotype. Post-mortem studies on humans have 
revealed a marked loss of PPO mRNA and orexins 
(Peyron et al., 2000; Thannickal et al., 2000), but 
narcolepsy-related genetic alterations are not really 
seen in prepro-orexin or orexin receptor genes 
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(Sakurai et al., 2010). The concomitant loss of 
prepro-dynorphin (Crocker et al., 2005) and the 
above data suggest that OX neurons are partly or 
completely lost as a part of the narcolepsy etiology 
(Sakurai et al., 2010). Narcolepsy correlates with 
certain HLA alleles (Kadotani et al., 1998), indicating 
that an autoimmune response might be responsible 
for OX neuron loss Kornum et al. (2011). When 
OX neurons are lost, the balance in the triangular 
complex between OX neurons, the sleep-inducing 
VLPO neurons, and wake-signaling monoaminergic 
neurons is changed. The communication between 
the VLPO and waking center continues without 
stabilizing signaling, and the phenotypic outcome 
Figure 5. The ‘Wake/sleep –triangle’ and mechanisms how OX neurons stabilize the wake/sleep states. The 
OX neurons, the monoaminergic neurons in the brain stem waking center, and the GABAergic neurons in the 
ventro-lateral preoptic nucleus (VLPO) are connected to each other in a triangular manner. 
In the wake state VLPO and monoaminergic waking center are reciprocally inhibiting each other. OX neurons 
send excitatory stimuli to the waking center which, in turn, maintain the inhibitory stimulus to the VLPO. The 
waking center also sends inhibitory stimuli to the OX neurons fine-tuning their activity. 
In the sleep state the VLPO neurons are activated and send inhibitory signals to OX neurons and the waking 
center to maintain sleep. 
In narcolepsy the loss of OX neurons leads to destabilization of the waking state and monoaminergic signaling 
output. The balance between the wake state and sleep state can change rapidly and patient falls asleep 
inappropriately. 
The grey arrows indicate activating signaling and the black arrows inhibitory signaling. Solid and broken arrows 
indicate the relative strength and weakness of the stimulus while sizes of the spheres indicate the relative activity 
of the indicated brain area. The picture is adapted from Sakurai T. et al., 2010.
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is inappropriate, flipping from wakefulness to sleep 
and vice versa (Sakurai et al., 2010).
1.4.3.4. The role of orexins and OX1 as regulators 
of apoptosis
In addition to regulation of metabolism and arousal, 
orexins relay potential apoptotic signals via OX1 
and OX2 receptors in CHO expression models, 
neuroblastoma cells, and colon carcinoma cells 
(Ammoun et al., 2006b; Rouet-Benzineb et al., 
2004; Voisin et al., 2011; Voisin et al., 2006). OX1 
is expressed in every tested colon cancer cell line, as 
well as primary tumors and metastases, but not in 
normal colonocytes or cells derived from patients 
with irritable bowel syndrome (Voisin et al., 2011). 
The molecular mechanism of apoptosis elicited by 
OX1 seems to be independent of an increase in [Ca
2+]
i (Ammoun et al., 2006b; Voisin et al., 2011), and 
relies on p38 MAPK (Ammoun et al., 2006b) and/or 
Src family kinases and SHP-2 tyrosine phosphatase 
(El Firar et al., 2009). This signaling activates 
the mitochondrial apoptosis pathway, including 
cytochrome c release and the activation of caspases 3 
and 7 (Rouet-Benzineb et al., 2004). The possibility 
to utilize aberrant expression of OX1 against colon 
carcinoma could enable the development of a 
novel type of therapy, given that the few theoretical 
obstacles (e.g. receptor desensitization) could be 
overcome (Laburthe et al., 2011).
1.5. The endocannabinoid system
The endocannabinoid system consists of 
endocannabinoids (eCBs), their GPCR-family 
receptors and the enzymatic machinery that 
synthesizes and degrades eCBs (Di Marzo, 2009). 
The hemp, Cannabis sativa, has for long been known 
to contain several psychoactive compounds. The 
most important and best characterized of these is 
Δ9-tetrahydrocannabiol (THC), which was isolated 
and described by Gaoni and Mechoulam in 1964. 
Subsequent intensive research led to the elucidation 
of the target of THC via the key discovery that small 
concentrations of cannabinoid drugs inhibited AC 
(Howlett, 1984; Howlett et al., 1984). These findings 
led to the suggestion of a signal transduction pathway 
being involved in the mechanisms of action of THC, 
in contrast to the earlier belief in altered membrane 
permeability induced by THC. Further evidence 
for the involvement of G-protein coupling came in 
later studies in which the requirement for Mg2+ and 
GTP and the sensitivity to pertussis toxin confirmed 
the Gi/o connection (Howlett, 1985; Howlett et 
al., 1986). The development of a stereoselective 
radiolabeled analogue [3H]-CP55940 eventually 
led to the discovery of the main targets of THC, 
the cannabinoid receptors (Devane et al., 1988). 
Cannabinoid receptor 1 (CB1) was cloned from rats 
(Matsuda et al., 1990) and from humans (Gerard et 
al., 1990) and cannabinoid receptor 2 (CB2) from 
HL60 promyelotic cells (Munro et al., 1993).
1.5.1. Endocannabinoid receptors and signal 
transduction
Cannabinoid receptors belong to the rhodopsin 
branch of the GPCR superfamily (Pertwee et al., 
2010). The distribution of CB1 and CB2 in the body 
is strikingly different: CB1 is almost exclusively 
expressed in neurons of the central nervous system 
(CNS) (Egertova et al., 2000; Herkenham et al., 
1990; Howlett et al., 2002; Matsuda et al., 1993), 
while CB2 is mainly found in immune cells and 
peripheral tissues (Munro et al., 1993). CB1 is also 
expressed in the liver, adipose tissue, reproductive 
organs, muscle, bone, and cardiac and vascular 
tissues, while some CB2 expression is found in the 
brain microglia (Pertwee et al., 2010). The existence 
of a third cannabinoid receptor is under debate 
(reviewed in Kano et al., 2009).
Rat CB1 consists of 473 amino acids, the human 
analogue of 472 and that in the mouse of 473 amino 
acids (Howlett et al., 2002). The sequence homology 
of CB1 between these three species is 97–99%. In 
humans, two N-terminal splice variants are known 
with different ligand-binding properties (Ryberg et 
al., 2005). Cannabinoid receptors are associated with 
the Gi/o family of G-proteins (Gi1,2,3 and Go1,2), and 
AC inhibition has been seen in most tissues and cells 
investigated (Howlett et al., 2002). In the presence 
of pertussis toxin, CB1 has been shown to stimulate 
AC, indicating that CB1 may be able to couple Gs in 
the absence of Gi (Glass et al., 1997). CB1 activation 
leads to the activation of the MAPK (ERK1/2) 
cascade (Bouaboula et al., 1995; Wartmann et al., 
1995). Depending on the cell type and the stimulus, 
the mechanisms leading to MAPK phosphorylation 
(and activation) can vary. In CHO cells, the pathway 
consisting of PI3K, protein kinase B (PKB/Akt), 
Raf-1, and MAPK/ERK kinase (MEK) is utilized 
for MAPK phosphorylation (Galve-Roperh et al., 
2002). In the N1E-115 neuroblastoma cell line, a 
CB1-induced reduction in cAMP and PKA activity 
reduced inhibitory c-Raf phosphorylation and 
stimulated MEK activation (Davis et al., 2003). 
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CB1 has been shown to activate p38 MAPK in 
hippocampal slice preparations (Derkinderen et al., 
2001) and human endothelial cells (Liu et al., 2000). 
In CHO cells, CB1 activates JNK and p38 (Rueda et 
al., 2000). The generation of nitric oxide (NO) upon 
CB1 stimulation has been documented in various cell 
types ( Jones et al., 2008; Prevot et al., 1998; Stefano 
et al., 1996), while in others, CB1 reduces NO levels 
(Cabral et al., 2001; Hillard et al., 1999). Signaling 
through CB1 has also been shown to regulate ion 
channels. CB1 activates inward-rectifying K
+ channels 
(Kir) and inhibits N-, P/Q- and L-type voltage-gated 
Ca2+ channels, mostly by direct Gβγ interaction with 
the channel (Howlett et al., 2002).
Endocannabinoids are also able to activate other 
endogenous receptors. Potential target receptors 
(‘non-CB’ receptors) include GPR55, opioid 
receptors, peroxisome proliferator-activated 
receptors (PPARs), and vanilloid type TPR channels 
(Kukkonen, 2011; Pertwee et al., 2010).
1.5.2. Metabolism of endocannabinoids
The discovery of cannabinoid receptors started 
intensive research to elucidate their endogenous 
ligands. The first ligand isolated was surprisingly a 
lipid instead of a peptide, as predicted. The molecule 
was an amide of arachidonic acid and ethanolamide, 
N-arachidonylethanolamide, and was named as 
an anandamide from a word meaning bliss in the 
Sanskrit language (Devane et al., 1992). It soon 
became evident that endogenous ligands were 
all lipid derivatives containing arachidonic acid. 
2-Arachidonylglycerol (2-AG) was found in 1995 
(Sugiura et al., 1995), 2-arachidonylglyceryl ether 
(noladin ether) in 2001 (Hanus et al., 2001), and 
virodhamine in 2002 (Porter et al., 2002) (Figure 
6.). In general, endocannabinoids are produced on 
demand at the site of need and are not usually stored 
in vesicles like classical neurotransmitters (Di Marzo, 
2009).
1.5.2.1. Biosynthesis
Anandamide biosynthesis in the neurons is a two-
step process. Ca2+-dependent N-acyltransferase (Ca-
NAT) transfers a fatty acid from the sn1-position of 
a glycerophospholipid to the primary amine group 
in phosphatidylethanolamine (PE) creating N-acyl 
PE (NAPE). Next, a specific NAPE-PLD hydrolyses 
NAPE to anandamide and PA (Okamoto et al., 2007). 
Ca-NAT is yet to be cloned, but NAPE-PLD was 
cloned in 2004 (Okamoto et al., 2004). The generation 
and analysis of NAPE-PLD-deficient mice (Leung et 
al., 2006) indicates the existence of an alternative 
pathway for anandamide biosynthesis. According 
to the hypothesis, NAPE is double-deacylated and 
the resulting glycerophosphate-NAE is hydrolyzed 
to glycerol-3-phosphate and anandamide (Simon 
et al., 2006). This reaction is inhibited by MAFP, 
Figure 6. Chemical structures of 
four common endocannabinoids.
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indicating the involvement of a serine hydrolase. 
Based on functional-proteomic analysis, α/β-
hydrolase-4 (ABH4) is proposed to be the lipase 
converting NAPE to GP-NAE. GP-NAE-cleaving 
activity in mouse brain and testis preparations has 
also been described (Simon et al., 2006). Together, 
ABH4 and ‘GP-NAE phosphodiesterase’ could 
constitute a NAPE-PLD-independent pathway 
for anandamide synthesis. Interestingly, a Ca2+-
independent NAT was recently discovered ( Jin et 
al., 2007), complicating the determination of the 
enzymes involved in anandamide biosynthesis.
2-AG is most likely produced via two separate 
metabolic pathways (Piomelli, 2003). The main 
pathway involves the PI-specific PLCβ and 
generation of 1,2-diacylglycerol (DAG), in which 
arachidonic acid is usually in the sn2 position. DAG 
has two metabolic fates. It can be converted to 2-AG, 
a monoacylglycerol, by sn1-specific DAG lipase 
(DAGL). So far, only two DAGLs have been cloned, 
DAGLα and DAGLβ (Bisogno et al., 2003). Both 
isoforms are sn1-specific, expressed in a wide variety 
of tissues and abundant in the brain. Interestingly, 
only DAGLα-knockout mice showed a marked 
reduction in 2-AG levels, both in the basal state and 
after stimulation, and deficient retrograde synaptic 
suppression (Gao et al., 2010; Tanimura et al., 
2010). Alternatively, DAG can be phosphorylated 
to phosphatidic acid by DAG kinase (DAGK). This 
ends the DAG signaling, but initiates other cascades 
related to the PA itself (see section 1.4.2.4.2 on PLD 
and PA). The alternative pathway for 2-AG synthesis 
starts with the phospholipase A1 (PLA1)-catalyzed 
production of 2-arachidonyl-lysophospholipid, 
which can be further hydrolyzed to 2-AG by 1-lyso-
PLC activity (Piomelli, 2003). Neuronal 2-AG 
production can be initiated by increasing [Ca2+]i. This 
was first shown in cultured rat hippocampal slices 
after high frequency stimulation. 2-AG synthesis was 
blocked by pretreatment with tetrodotoxin (TTx) 
and the removal of the external Ca2+ (Stella et al., 
1997).
1.5.2.2. Degradation
Anandamide signaling is mainly terminated by fatty 
acid amide hydrolase (FAAH) (Cravatt et al., 1996; 
Deutsch et al., 1993; reviewed in Deutsch et al., 
2002). FAAH is an integral membrane protein with 
relatively broad substrate selection. It hydrolyzes 
NAEs, other bioactive fatty acid amides, and 2-AG, 
but anandamide appears to be the preferred substrate 
(Ueda et al., 1995). FAAH is mainly expressed in 
the liver, followed by the brain, small intestine and 
testis (Deutsch et al., 2002). Anandamide levels in 
FAAH-knockout mice are highly elevated (Cravatt 
et al., 2001), confirming the central role of FAAH 
in anandamide degradation. Anandamide can also 
be degraded by the NAE-hydrolyzing acid amidase 
(NAAA) (Tsuboi et al., 2005), which is localized 
in lysosomes instead of the plasma membrane. The 
tissue expression of the NAAA also differs from 
that of FAAH. NAAA mRNA is mostly expressed 
in the prostate, leukocytes, spleen, liver, kidneys, 
and pancreas (Ueda et al., 2010), indicating possibly 
distinct physiological roles for these two anandamide-
degrading enzymes.
Multiple enzymatic species are able to hydrolyze 
2-AG in vitro, including FAAH (Goparaju et al., 
1998), neuropathy target esterase (NTE) (van 
Tienhoven et al., 2002), and monoacylglycerol lipase 
(MAGL) (Dinh et al., 2002). However, about 85% of 
the brain 2-AG is hydrolyzed by MAGL (Blankman 
et al., 2007). The remaining 15% was found to 
be hydrolyzed by the previously uncharacterized 
enzymes ABHD6 and ABHD12 (α/β-hydrolase 
domain containing 6 and 12, respectively), suggesting 
that these three enzymes are the regulators of 2-AG 
levels in vivo (Blankman et al., 2007).
Endocannabinoids are also metabolized 
by lipoxygenases (12-LOX and 15-LOX), 
cyclooxygenases (COX-2), and cytochrome 
P450 (Rouzer et al., 2011). The physiological 
significance of this interaction is unknown, but in 
theory the cross-talk between endocannabinoid 
and eicosanoid systems could occur by several 
ways. Endocannabinoids could be hydrolyzed to 
provide AA precursor for eicosanoid biosynthesis. 
Oxygenated endocannabinoids could directly 
activate eicosanoid or endocannabinoid receptors, 
or they could be hydrolyzed and then bind to these 
receptors. Alternatively, there could be distinct 
receptor(s) for oxygenated endocannabinoids, and 
finally, oxygenation can function as a mechanism 
to terminate endocannabinoid signaling. There are 
experimental data supporting the role of COX-2 in the 
termination of endocannabinoid signaling (Rouzer 
et al., 2011). Some pharmacological evidence of a 
putative receptor also exists (Rouzer et al., 2011). 
However the interactions of endocannabinoid and 
eicosanoid systems remain poorly defined and 
further studies are required to clarify the issue.
Although anandamide was the first endocannabinoid 
discovered, the current view is that it is 2-AG and not 
31
anandamide that is the primary endocannabinoid 
and CB1 ligand in the CNS. The 2-AG concentration 
in the CNS is about 800 times higher than that 
of anandamide (Sugiura et al., 1995), and 2-AG 
exhibits full agonist behavior toward CB receptors, 
while anandamide only functions as a partial agonist 
(Hillard, 2000).
1.5.3. Physiology of the endocannabinoid 
system
The endocannabinoid system (ECS) has been 
connected to the regulation of several physiological 
processes, including food intake and energy balance, 
at both central and peripheral levels (Di Marzo 
et al., 2005). It has been known for centuries that 
cannabis consumption induces feeding and a 
preference for palatable food. Systemic stimulation 
of CB1 by THC or pharmacological analogues or 
endocannabinoids stimulates feeding (Williams et 
al., 1999; Williams et al., 1998) and the blockade of 
CB1 by rimonabant (SR141716A), the first selective 
CB1 antagonist discovered (Rinaldi-Carmona et 
al., 1994), suppresses the agonist-induced effect 
and reduces the overall food intake, even in starved 
animals (Colombo et al., 1998). The observation 
that CB1-knockout mice consume less food (Di 
Marzo et al., 2001) supports the concept of eCBs as 
regulators of feeding. Hypothalamic ECS is activated 
transiently after fasting, resulting in an increased 
food intake (Di Marzo et al., 2005). The effects 
of eCBs in the CNS are directed toward the brain 
areas regulating energy homeostasis, especially the 
orexinergic systems in the lateral hypothalamus and 
paraventricular hypothalamic nucleus (Kirkham 
et al., 2002), and mesolimbic areas involved in 
hedonistic or motivational food intake (e.g. the 
desire for food) relayed by the nucleus accumbens 
and ventral tegmental area (Di Marzo et al., 2005; 
Quarta et al., 2011).
Endocannabinoids are known to act as retrograde 
regulators of synaptic transmission (Kano et al., 2009; 
Ohno-Shosaku et al., 2011). Endocannabinoids are 
synthesized in postsynaptic neurons in response 
to a depolarization-induced increase in [Ca2+]i. 
Cytosolic eCBs are transported out via the putative 
eCB transporter to act on CB1 receptors expressed 
in presynaptic and/or nearby neurons. CB1 signaling 
inhibits voltage-gated Ca2+ channels and activates Kir 
channels, and thus efficiently attenuates presynaptic 
depolarization and subsequent neurotransmitter 
release (Kano et al., 2009). The outcome of retrograde 
modulation can also be the activation of relevant 
neurons via depolarization-induced suppression 
of inhibition (DSI) when CB1-expressing neurons 
are GABAergic (Kano et al., 2009). It is likely that 
retrograde modulation exerts the regulatory effects 
of eCBs in the CNS (Figure 7.).
ECS also participates in the regulation of energy 
homeostasis in the peripheral tissues (Silvestri et 
al., 2011). During food deprivation, the synthesis 
of anandamide and 2-AG is increased in the small 
intestine and levels return to the baseline after 
feeding. Similar alteration has been shown to occur 
in the hypothalamus (Matias et al., 2006). In adipose 
tissue, CB1 stimulation induces the differentiation 
of preadipocytes, uptake of glucose and activation 
of several enzymes involved in anabolic fatty 
acid metabolism, including lipoprotein lipase 
and fatty acid synthase (Matias et al., 2008b). 
Endocannabinoids also affect energy metabolism in 
the liver, skeletal muscle and pancreas (Matias et al., 
2008a). Endocannabinoids have additionally been 
implicated in the regulation of the brain–gut axis, a 
neuronal and humoral system connecting the CNS 
and GIT in a reciprocal manner (Storr et al., 2007). 
During feeding, the GIT secretes the antiorexigenic 
hormones choleocystokinin (CCK) and peptide YY 
( PYY) into the circulation (Suzuki et al., 2010). They 
act on the area postrema within the brain stem and 
the arcuate nucleus in the hypothalamus, both areas 
unprotected by the blood–brain barrier (Suzuki et 
al., 2010). Endocannabinoids are suggested to act 
through the CB1 located in the cell bodies of vagal 
afferent neurons in nodose ganglia (Burdyga et al., 
2004). CB1 levels in the nodose ganglion are varied in 
relation to the nutritional status. They are upregulated 
during fasting and downregulated after feeding 
(Burdyga et al., 2010), probably by a CCK-mediated 
mechanism (Burdyga et al., 2004). Interestingly, 
the inhibitory action of CCK is reverted by OxA, 
ghrelin and anandamide (Burdyga et al., 2010). BAT 
appears to be under endocannabinoid control. A 
systemic blockade of CB1 with rimonabant increases 
BAT activity (Quarta et al., 2010), and the effect is 
mediated by sympathetic innervations of BAT.
Recent progress in ECS physiology has revealed its 
key role in the pathophysiology of obesity (Di Marzo 
et al., 2005; Quarta et al., 2011). According to the 
current view, obesity is a complex disease involving 
disrupted homeostatic signaling, the accumulation 
of excessive fat and chronic low-grade inflammation 
(Weisberg et al., 2003). The ECS appears to be 
hyperactive in obesity, which manifests as increased 
feeding and desire for food and accelerated lipogenesis. 
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Dysfunction of insulin and leptin signaling in obesity 
is likely to play a part in ECS hyperactivity. Leptin 
is a known regulator of cEBs in the CNS (Di Marzo 
et al., 2001) and in white adipose tissue (Buettner et 
al., 2008). Insulin also down-regulates the levels of 
eCBs in adipocytes (D’Eon et al., 2008; Murdolo 
et al., 2006). The ECS is additionally implicated in 
the generation of the inflammatory status related 
to obesity by disturbing intestinal permeability and 
possibly by directly interacting with the immune 
system via CB2 receptors (reviewed in Cluny et al., 
2012). Endocannabinoids have been shown to 
directly alter the localization of the key components 
in epithelial tight junctions and work in concert with 
gut microbiota (Muccioli et al., 2010). An overactive 
ECS and high-fat diet together lead to the leakage of 
lipopolysaccharides from the gut (Cani et al., 2007; 
Cluny et al., 2012) and activation the innate immune 
system through toll-like receptors (Lumeng et al., 
2011), leading to chronic inflammation.
The endocannabinoid system can therefore be 
considered as an evolutionary adaptation aimed 
maximizing the outcome from a meal by optimizing 
nutrient intake and storage, and by reducing energy 
expenditure. In the modern age, when food is rarely 
scarce, this very efficient system is easily disturbed, 
resulting in obesity and associated metabolic 
disorders such as type II diabetes, which has reached 
epidemic proportions in countries with Western life-
style.
Figure 7. Orexins participate in the retrograde regulation of the synaptic transmission. Arriving action potential 
initiates the release of OxA via Ca2+ -controlled manner. OxA binds to the OX1 (black) on the postsynaptic 
neuron leading to increase in intracellular Ca2+ and the production of 2-AG via PLCβ/DAGL pathway. The 2-AG 
then diffuses out of the cell and binds to CB1 receptor (grey) on nearby GABAergic neuron. CB1 signaling leads 
to the attenuation of the GABA release and subsequent alleviation of the inhibitory GABA-signaling upon the 
target neuron. The overall outcome is enhanced activity of the OX1-bearing neuron.
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2. AimS Of the Study
Stimulation of OX1 orexin receptor has been shown 
to activate PLC and PLD ( Johansson et al., 2008; 
Johansson et al., 2007). The original aim of this 
study was to investigate the involvement of PLA2s in 
orexin receptor signaling, to develop techniques to 
assess PLA2 activity and later examine the possible 
connection to endocannabinoid production. The 
specific aims therefore were to:
3.2. Conventional arachidonic acid 
and oleic acid release
CHO-hOX1 cells at a density of 30 000 cells per well 
were plated on a 24-well plate and grown overnight 
in regular medium. The next day, the cells were 
labeled with 3H-AA (0.1 µCi/well) overnight. Prior 
to the experiment, the wells were washed twice with 
250 µl HBM (Hepes-buffered medium) containing 
lipid-free BSA (0.24 mg/ml), 200 µl HBM+BSA 
was added, and the cells were activated with 50 µl 
of HBM containing 5× concentrations of OxA or 
thapsigargin. The 24-well plates were immediately 
transferred to an incubator for 7 minutes, after which 
200 µl of medium was collected into Eppendorf 
tubes, centrifuged briefly, and 100 µl of supernatant 
was transferred to a scintillation vial along with 3 ml 
of scintillation cocktail. The samples were analyzed 
for radioactivity with a liquid scintillation counter.
3.3. Filtration assay for 
arachidonic acid release
In order to speed up the throughput and make AA 
analysis less laborious, we developed a semi-high-
throughput assay based on a filtration technique 
(Paper IV). Briefly, CHO cells were grown in dishes 
and loaded with [3H]-AA 16 h before the experiments, 
as described in the section “Conventional 
arachidonic acid release” (3 µCi/dish). The next day, 
the cells were washed with HBM containing 2.4 mg/
ml lipid-free BSA, detached with PBS containing 
0.68 mM ethylenediaminetetraacetic acid (EDTA), 
counted and resuspended in HBM containing lipid-
1) To investigate the involvement of PLA2 in orexin 
receptor signaling;
2) To confirm which PLA2 subspecies are activated 
and which other enzymes might be activated;
3) To develop a more practical and rapid assay for 
PLA2 activity measurement;
4) To investigate the possible connection between 
OX1 and endocannabinoid synthesis;
5) To develop an artificial cell-cell communication 
assay to measure the biological relevance of the 
2-AG produced.
3.1. Cell culture
Chinese Hamster Ovary (CHO) cells expressing 
human OX1 receptor (CHO-hOX1) were used in 
Papers I, II and IV, and CHO cells expressing human 
CB1 receptor (CHO-hCB1) in Paper II. The cells were 
grown in Ham’s F12 medium supplemented with 
10% fetal calf serum (FCS), 2 mM UltraGlutamin, 
100 U/ml penicillin and 80 U/ml streptomycin. 
G418 (0.4 mg/ml) was used as a selection marker 
for CHO-hOX1 and zeocin (0.25 mg/ml) for CHO-
CB1.
HEK293 cells expressing human OX1 receptors and 
wild-type HEK293 cells were used in Papers III and 
IV, respectively. Cells were cultured in Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% 
fetal calf serum (FCS), 2 mM UltraGlutamin, 100 
U/ml penicillin and 80 U/ml streptomycin. In 
HEK293-OX1 cells, hygromysin (0.05 mg/ml) was 
used as a selection marker.
Jurkat E6-1 T cell-derived lymphoma cells and HEL 
92.1.7 erythroblast leukemia cells were grown in 
RPMI-1640, supplemented with 10% FCS, 2 mM 
UltraGlutamin, 100 U/ml penicillin and 80 U/ml 
streptomycin. The medium was renewed every two 
or three days (Paper IV).
All cell lines were grown in a humidified incubator at 
+37 °C and in 5% CO2. Adherent cells were continued 
on plastic cell culture dishes with a bottom area of 56 
cm2, in 6-well plates (for TLC, Paper III) or 24-well 
plates (for AA release and cell-cell communication 
assay; Papers I, II and III). Suspension cells were 
continued in 200-ml cell culture flasks (Paper IV).
3. mAteRiAlS And methOdS
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free BSA. The cells were plated onto filter-bottomed 
96-well plates (100 µl and 100 000 cells per well) 
containing the agonists. After 7-min incubation, the 
supernatants were collected on another 96-well plate 
by filtering using a vacuum manifold. Samples were 
collected into scintillation vials and the radioactivity 
assessed by scintillation counting.
3.4. cAMP measurement and the 
2-AG reporter assay
cAMP was assessed utilizing a well-established 
method. CHO-hCB1 cells were labeled with 
3H-
adenine (5 µCi/ml) for 2 h before the experiment 
in normal culture medium. The cells were then 
detached from the dish, counted and resuspended to 
a concentration of 1×106 cells/ml in HBM containing 
0.5 mM 3-isobutyl-1-methylxanthine (IBMX) for 10 
minutes. Next, 100 µl aliquots (100 000 cells) were 
dispensed with a stepper pipette into a 96-well plate 
containing forskolin and/or various concentrations 
of CB1 agonists and antagonists. After 10 minutes 
of incubation at +37 °C, the cells were centrifuged 
down, the supernatant discarded and cells were 
lysed with perchloric acid and rapidly frozen. After 
thawing, the plate was centrifuged again to pellet 
any debris, and 125 µl of supernatant was exposed 
to Dowex/Alumina chromatography for collection 
of 3H-ATP+3H-ADP and 3H-cAMP fractions, which 
were then analyzed by scintillation counting.
The same method was applied for the 2-AG 
reporter assay utilizing CHO-CB1 cells as the 2-AG 
production-dependent cAMP reporter. Briefly, 
CHO-hCB1 cells were labeled with 
3H-adenine as 
above, detached and plated onto CHO-hOX1 cells 
cultured on 24-well plates by gentle centrifugation. 
The cell pool was stimulated with forskolin (acting on 
CHO-hCB1 cells) and OxA (acting on CHO-hOX1 
cells) and the cAMP production was determined 
after incubation for 10 min as above.
3.5. Ca2+ imaging
For Ca2+ measurements, CHO-hOX1 cells were 
grown on 24-well plates on top of polyethyleneimine-
coated glass coverslips overnight. Prior to the 
experiment the cells were loaded with 4 µM fura-2 
acetoxymethyl ester for 20 min at +37 °C in HBM 
containing 1 mM probenecid, rinsed once with HBM 
and immediately placed in a perfusion chamber. 
Ca2+ measurements were performed at +35 °C 
using a Nikon TE2000 fluorescence microscope 
(20×/0.75 air objective) and Andor iXon 885 
EM-CCD camera under the control of Nikon NIS 
Elements AR software with a 6D extension (Paper 
II). For Ca2+ imaging, the cells were excited with 
alternating 340 and 380 nm light (Sutter DG4 Plus) 
and the emitted light was collected through a 400-
nm dichroic mirror and a 450-nm long-pass filter 
(Paper II). In Paper I, another imaging system was 
used in an equal manner. All chemical additions were 
made by constant perfusion (HBM + probenecid). 
When the inhibitors tetrahydrolipstatin (THL) and 
pyrrophenone were tested, the cells were pretreated 
with them for 20 min, and they were included in the 
perfusion medium as well. Regions of interest were 
defined in NIS software. Data were transferred to 
Microsoft Excel for visualization and quantization.
3.6. Thin layer chromatography
For TLC (thin layer chromatography) experiments, 
250 000 CHO-hOX1 cells were grown overnight on 
6-well plates. The cells were labeled with 14C-AA (0.2 
µCi/ml) in cell culture medium (Ham’s F12) 16 h 
prior to the experiments. 14C-AA loading medium 
was removed, the cells were washed twice with 
HBM + S-BSA (2.4 mg/ml) and stimulated with 
OxA for 7 min. Supernatants from the cells were 
rapidly removed and spun down to remove detached 
cells. The lipids were extracted from the supernatant 
with a slightly modified Bligh and Dyer method. 
The final phase was collected and dried under a 
stream of N2. The dried lipids were dissolved in 
chloroform and the samples run on TLC plates with 
ethylacetate:methanol (90:10). TLC plates were 
quantitated both by plate imaging and scintillation 
counting, both of which gave comparable results.
35
4.1. AA release and PLA2 activation 
(Papers I and II)
We observed a robust release of 3H-radioactivity from 
3H-AA-labeled CHO-hOX1 cells in response to OxA 
or OxB stimulation (Paper I). This “3H-overflow” 
(as we coined it in Paper II to distinguish it from 
the actual AA release visualized using TLC) was 
orexin concentration-dependent. The 3H overflow 
was readily inhibited by 10 µM MAFP (Paper I), 
but we were able to get potent inhibition even with 
submicromolar concentrations (Paper II). MAFP, 
although often used as a selective PLA2 inhibitor, is 
an AA analogue and irreversible inhibitor of PLA2 
enzymes (and all other enzymes utilizing AA as a 
substrate). Partial inhibition was obtained with two 
other inhibitors of iPLA2, R- and S-BEL; however, 
neither of these inhibitors may be very selective for 
iPLA2. Due to the Ca
2+sensitivity of the response, 
although there could also be other explanations 
for this (Ammoun et al., 2006a; Jäntti et al., 2011; 
Johansson et al., 2007), and the involvement of the 
ERK cascade (see below), cPLA2 appeared to be a 
more likely player than iPLA2. Thus, based on the 
results of Paper I, we could not firmly confirm any 
enzyme species responsible for the apparent AA 
release. However, the fact that the concentration–
response curves observed were biphasic suggested 
that two different cascades could contribute to them.
In Paper II, the cascades were further examined. 
3H-AA overflow was shown, in a complementary 
manner, to be fully inhibited by pyrrophenone 
(cPLA2 inhibitor) and THL (DAGL inhibitor). TLC 
experiments confirmed that indeed the AA overflow 
was composed of both 2-AG (produced from DAG 
by DAGL) and free AA (produced both from PL 
hydrolysis by cPLA2 and from 2-AG hydrolysis by a 
MAGL-like activity). cPLA2 activity seemed to take 
place at lower orexin concentrations than DAGL 
activity, suggesting an explanation for the biphasic 
concentration–response curves observed in Paper I. 
In Paper I we could also see that the potency of OxA 
to stimulate 3H-overflow from 3H-oleic acid-labeled 
cells was significantly lower than from 3H-AA-labeled 
cells. In Paper II we could verify using THL that this 
indeed was due to the fact that 3H-oleic acid was only 
released by the DAGL pathway, most likely by DAGL 
itself. Circumstantial evidence from the potency also 
supports the involvement of DAGL.
In paper I we also demonstrated that 3H-AA overflow 
was attenuated by treatment with MEK1 inhibitors. 
MEK is the immediate upstream activator of ERK1/2. 
Both U0126 and PD98059 markedly reduced the 3H-
AA overflow in CHO-hOX1 cells. Phosphorylation 
of Ser505 in cPLA2 by MAPK is known to be crucial 
for cPLA2 activation (Lin et al., 1993). On the other 
hand, OX1 strongly activates ERK1/2 in CHO 
cells (Ammoun et al., 2006a). It is thus tempting to 
speculate that coupling of OX1 to MAPK represents 
a cross-talk between these two signaling pathway. We 
had interest in this pathway and we tried to explore 
it by two means. Firstly, we wanted to assess the 
phosphorylation by western blotting. Unfortunately, 
no direct antibodies were available for pSer505-
cPLA2α (and at the time we were not entirely sure 
that this was likely to be the isoform). Secondly, 
we tried to assess the involvement of Ser505 in the 
overexpression of a mutant of cPLA2α, the Ser505Ala 
mutant. We obtained this clone from another lab 
that had used it long ago. The plasmid could not be 
amplified, even in bacteria, and since no information 
was available on it, we did not continue along this 
line.
4.2. PLA2 and ROC (Papers I, II 
and III)
One of the central aims of this thesis was the 
identification of the mechanisms of OX1-mediated 
ROC activation in CHO-hOX1 cells. We discovered 
that cPLA2 activity was absolutely needed for the 
major part of the ROC response, as judged by the 
imaging data with pyrrophenone (Paper II) and 
earlier with MAFP (Papers I and III). The inhibition 
of DAGL activity by THL did not affect ROC influx 
(Paper II).
It is therefore likely that the products of the cPLA2 
reaction, AA or LPC or some of their metabolites, 
act as mediators of OxA-induced ROC activation 
in CHO cells. ARC and many TRP channels are 
regulated by AA, and LPA is likewise indicated in 
the regulation of some TRP channels (reviewed in 
Kukkonen, 2011). LPC is also indicated in activating 
non-store-operated Ca2+ channels in eosinophilic 
granulocytes (Zhu et al., 2007). It is thus feasible 
that the ROC response elicited by OxA in CHO-
hOX1 cells is a result of LPC action and not that of 
AA. ROC inhibition by pyrrophenone does not 
reveal the downstream component, but only the 
enzymatic activity producing it. On the other hand, 
DAG has been shown to regulate TRPC channels in 
IMR-32 neuroblastoma cells transiently expressing 
OX1 (Nasman et al., 2006). If this was also the case 
4. ReSultS And diSCuSSiOn
36
SuMMARy
with CHO cells, THL treatment would have been 
expected to increase ROC influx, as THL should 
increase DAG levels. We did not see any significant 
differences between the control cells and THL-treated 
cells, or less inhibition after incubating pyrrophenone 
and THL together compared to pyrrophenone alone. 
This interpretation is not straightforward and has 
shortcomings. Increased levels of DAG followed by 
THL treatment would also activate PKC, and PKC is 
known to inhibit many TRPC channels (Trebak et al., 
2005; Venkatachalam et al., 2003). It is also possible 
that the production of DAG was already saturated 
at 0.3 nM OxA in the control cells and the effect of 
THL may therefore have been beyond the detection 
limits of the experimental setup used. This subject 
is of interest and should be investigated in detail in 
a more suitable experimental protocol including a 
wider concentration range of OxA.
In HEK-293 cells expressing recombinant OX1 
receptors, exposure of the cells to OxA induced Ca2+ 
oscillations (Paper III). The oscillations required 
extracellular Ca2+. The oscillations induced by a low 
concentration (1 nM) of OxA were investigated 
in detail. Previous studies with dominant-negative 
TRPC channel constructs have suggested that 
OxA-induced ROC activity relies at least in part 
on TRPC3/6 channels in CHO and IMR-32 cells 
(Larsson et al., 2005; Nasman et al., 2006). The 
strongest suppression of oscillations in HEK cells 
was obtained using the dominant-negative TRPC3 
construct, pointing out the putative role of TRPC3 
in OxA-induced oscillations. Mg2+ (10 mM) led 
to full inhibition in a reversible manner. MAFP 
fully attenuated Ca2+ oscillations induced by 1 nM 
OxA in HEK293 cells. Consequently, we measured 
3H-overflow from 3H-AA-labeled HEK cells, and 
observed that this was significantly stimulated both 
at low and high OxA concentrations. The addition of 
exogenous AA restored oscillations in the presence 
of MAFP, although these became dissynchronized. It 
was thus concluded that at low OxA concentrations, 
Ca2+ oscillations occur in a manner dependent on 
Ca2+ influx via Mg2+-sensitive ROC channels, but not 
SOCs (or, probably, Ca2+ release). In addition, AA 
release would be required for the response. However, 
MAFP is an irreversible inhibitor of PLA2s (and 
several other AA-metabolizing serine hydrolases). It is 
therefore peculiar how a brief wash is able to remove 
MAFP-induced inhibition of Ca2+ influx. If AA was 
indeed important for the oscillatory response, MAFP 
might act as a direct antagonist for the AA binding 
site of, for instance, a channel protein from the 
extracellular side. AA perfusion could compete with 
MAFP removal from the channel, thus explaining 
the restoration of the Ca2+ influx. Dissynchronized 
oscillations might result because perfusion with 10 
µM AA does not necessarily mimic the physiological 
concentrations of AA required for proper oscillations 
in HEK293 cells.
4.3. 2-AG release (Paper II)
As described above (4.1.), we were able to demonstrate 
in Paper II that the potent endocannabinoid 2-AG 
was also produced by OX1 receptor activity in CHO-
hOX1 cells. 2-AG production was not only verified 
by the pharmacological evidence and TLC, but also 
utilizing the CB1 receptor-based artificial cell-cell 
communication assay (also referred to as the 2-AG 
reporter assay). In this assay, we were able to show 
that the 2-AG produced in CHO-hOX1 cells upon 
OX1 receptor stimulation effectively exited the cells 
and stimulated CB1 receptor in nearby cells (Paper 
II). This situation is basically similar to retrograde 
synaptic transmission occurring in the brain.
The finding was of interest, but somewhat expected. 
Orexin receptors strongly activate PLC and PLD, 
with an ample supply of DAG ( Johansson et al., 
2008), and DAGL is also suggested to be activated 
by Ca2+ elevation. Thus, Gq-coupled GPCRs have 
been shown to be able to stimulate 2-AG production 
in previous studies (Kim et al., 2002; Maejima 
et al., 2001; Parrish et al., 2006). In the work by 
Parrish and colleagues, the stimulation of 5-TH2A in 
NIH3T3 cells led to the activation of PLC and an 
increase in [Ca2+]i, both of which were needed for 
2-AG production. The centrality of Ca2+ for 2-AG 
production has also been noted in the comprehensive 
review of endocannabinoids by Kano et al. (2009). In 
our CHO cells, although both PLC and PLD were 
strongly activated by OX1 receptor stimulation ( Jäntti 
et al., 2011; Johansson et al., 2008; Johansson et al., 
2007; Lund et al., 2000), mainly PLC contributed 
to the 2-AG release (Paper II). We could not detect 
any anandamide release from CHO-hOX1 cells (not 
shown). This is interesting, since an increase in [Ca2+]
i is also considered to be important for anandamide 
biosynthesis (Piomelli, 2003). A likely explanation 
for this is that CHO cells do not express the enzymes 
needed for anandamide biosynthesis or release.
While physiological evidence points to the definitive 
collaboration of OX1 and 2-AG (see 4.4.), it is 
difficult to prove with slice preparation that 2-AG 
is produced in OX1-expressing neurons. Complex 
neuronal connections leave open the possibility that 
2-AG is produced by other nearby neurons receiving 
simultaneous excitatory inputs or by neurons released 
from inhibitory inputs. Therefore, direct biochemical 
evidence from OX1-expressing cell lines provides 
significant proof of the ability of OX1 receptors to 
induce 2-AG biosynthesis and release.
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4.4. Endocannabinoid system and 
orexin system connections
Indirect evidence for the connection of 
endocannabinoid and orexinergic systems was already 
provided in 2005. The work performed with OxB in 
dorsal raphe nucleus slice preparations demonstrated 
that OxB could inhibit glutamatergic synaptic currents 
in 5-HT neurons. This inhibition was mimicked 
by WIN 55,212-1, a synthetic CB1 receptor agonist 
and blocked by AM-251, a known CB1 antagonist, 
strongly pointing to endocannabinoid-relayed 
retrograde regulation (Haj-Dahmane et al., 2005). 
Similar results were obtained in rat ventrolateral 
periaqueductal gray (vlPAG) slices (Ho et al., 2011). 
OxA inhibited GABAergic nociception in vlPAG via 
a putative retrograde regulation mechanism.
Hilairet and coworkers explored the potential cross-
talk of OX1 and CB1 receptors in CHO cells (Hilairet 
et al., 2003). Three stable cell lines expressing OX1, 
CB1 and both receptors together were created. 
All constructs were well expressed on the plasma 
membrane and clear colocalization of OX1 and CB1 
were observed in OX1−CB1 cells. A massive increase 
in the potency of OxA to activate ERK was observed 
in OX1−CB1 cells as compared to OX1-expressing 
cells. The effect was blocked by the CB1 antagonist 
rimonabant. Their conclusions was that OX1−CB1 
receptors dimerized, as, according to the authors, 
the possibility of the presence of endogenous 
cannabinoids mediating the interaction was ruled 
out based on earlier work (Bouaboula et al., 1997). 
The receptor dimerization model was later refined 
in (Ellis et al., 2006) and in (Ward et al., 2011). Both 
studies presented data supporting the idea of OX1 
and CB1 forming heterodimers when coexpressed in 
the same cell. As in the study by (Hilairet et al.), Ellis 
and coworkers also documented an increase in OxA-
induced ERK activation in OX1−CB1 coexpression in 
HEK293 cells. However, the potentiation was much 
less significant in HEK293 cells.
However, (Hilairet et al.) made a false assumption 
that their CHO OX1−CB1 expression system would 
be devoid of endocannabinoids. In the study by 
Bouaboula et al. (1997), only CHO-CB1 cells and 
not CHO cells expressing both receptors were used. 
Also, the fact that introducing Gq-coupled receptors 
to the expression system and the following receptor 
stimulation could elevate endicannabinoid levels 
was not considered. Our finding that OX1 is able to 
activate 2-AG production opens up a comprehensive 
alternative interpretation of their data. Both OX1 
and CB1 have been shown to activate ERK upon 
ligand binding (Ammoun et al., 2006a; Bouaboula 
et al., 1995), and signaling cascades derived from 
OX1 and CB1 could thus converge at the MAPK 
level. In addition, recent evidence supports the 
view that endocannabinoids are able to act in an 
auto- or paracrine manner, and that the most likely 
explanation for the so-called constitutively active 
CB1 receptor is indeed the presence of endogenously 
produced endocannabinoids (reviewed in Howlett et 
al., 2011). We clearly demonstrated in our cell−cell 
communication assay that OX1 stimulation is able to 
elevate 2-AG in biologically relevant quantities and 
even act via CB1 receptors in nearby cells (Paper II). 
It is thus very likely that the increase in the potency 
of OX1 for ERK phosphorylation at least partly 
results from 2-AG-mediated activation of CB1 and 
subsequent signaling to ERK. The potentiation of 
ERK activation after coexpressing OX1 and CB1 may 
not therefore require receptor heterodimerization, as 
suggested by Ellis et al. (2006), but a simple soluble 
substance, 2-AG, acting on CB1 receptors and creating 
a feed-forward regulation resulting in the reported 
potentiation of OxA-relayed ERK activation. It is, 
however, conclusive that the presense or absence of 
receptor dimerization could not be verified or ruled 
out by this study.
The same chain of deduction is presented in Ellis 
et al. (2006). The authors also failed to include the 
possibility of endogenous production of CB1 substrate 
acting back on CB1 receptor, which is the most logical 
explanation for the potentiation of ERK activation by 
OxA during the heterologous coexpression of OX1 
and CB1. Their theory that heterodimerization of 
GPCRs could alter the pharmacological properties of 
the corresponding receptors is interesting.
Nevertheless, our finding of OX1-induced 2-AG 
production (Paper II) raises questions about the 
suitability of the OX1-CB1 coexpression system 
used in Ellis et al.(2006) and Ward et al.(2011) 
to draw conclusions about alterations in the 
heterodimerization-induced pharmacological 
properties of GPCRs, even if the heterodimerization 
of the receptors was indeed verified.
4.5. AA release measurement 
methodology (Paper IV)
The measurement of AA release in a 24-well system 
is quite a laborious and time-consuming procedure. 
We therefore aimed to develop faster and easier 
methods to asses AA release (Paper IV). The assay 
was scaled down to 96-well plates giving four times 
more samples per plate. Another advantage of 96-
well plates is the ability to design more complex 
experimental layouts. A further innovation was to 
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utilize filter-bottom plates and a vacuum manifold or 
centrifugation to speed up the most time-consuming 
wash steps in the protocol. The filter retains cells but 
allows the molecular components of the supernatant 
pass through. This also removes the centrifugation 
step needed in the conventional AA release protocol 
to remove detached cells.
Use of the filtration method also reduces the variation 
in the results. The cells are applied to the wells as a 
suspension. This ensures that an equal quantity of 
cells is more likely present in each well than if they 
were washed several times, as in the conventional 
AA release method. The use of suspended cells 
also overcomes the problem of detachment of cells 
during the various washes. This enables the use of 
fewer parallel samples, and more questions can be 
addressed per experiment without worrying about 
day-to-day variation between the experiments.
A requirement for this system is the use of cell 
suspensions. The detachment of adherent cells for 
the assay might affect their cellular physiology via 
altered cytoskeleton assembly and morphology. 
We nevertheless consider that if relatively simple 
pharmacological analyses of receptor functions are 
carried out, as described in Paper IV, the artifacts 
should not be too severe and the assay should remain 
scientifically reliable. The advantage in the use of the 
filter-based AA-release assay is the ability to also apply 
the method to naturally suspension-grown cells, such 
as blood cells and blood cell-derived cell lines. We 
tested both Jurkat E6-1 and HEL 92.1.7 cells for AA 
release and found them to respond to suitable stimuli 
and produce detectable amounts of AA.
One limitation of the filtration method is the one-
time nature of the filtration. We varied the level of 
the vacuum and the relative centrifugal force, but 
the cells nevertheless became unresponsive after 
the first removal of fluids. We assume that some 
kind of minor damage or morphological change 
caused by the filtration were responsible for the 
unresponsiveness. The plasma membrane, however, 
appears to remain intact. We could not detect any 
major increase in radioactivity in the samples after a 
second filtration/centrifugation step, indicating that 
no excessive leakage occurred. The basal release in 
the filtration method was slightly increased compared 
to the conventional method. The reason for this is 
unknown, but might relate to the detachment of the 
cells for the assay.
The nature of the leaking substance (= basal 
release seen in the “3H overflow” measurements) 
is unknown. According to the TLC data, this 
radioactivity originates neither from AA nor 2-AG. 
This is interesting, but proper investigation of this 
issue requires a mass-spectrometry approach.
Figure 8. Summary of the intracellular signaling events upon OX1 challenge. The binding of OxA to the OX1 
initiates Ca2+ entry to the cell cytoplasm from both intracellular stores (via PLCβ and IP3 pathway) and 
extracellular sources via receptor-operated channel activated by an unknown cPLA2 product (possibly AA). In 
addition, another lipid-derived signaling component, 2-AG, is produced upon the OX1 stimulation. The increased 
intracellular Ca2+ concentration activates cPLA2, but phosphorylation of cPLA2 by OX1-activated ERK might 
also be needed for its full functionality.
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Stimulation of OX1 receptors with OxA was shown 
to activate robust AA release via a cPLA2-mediated 
pathway in CHO-hOX1 cells. cPLA2 activity was also 
required in the OxA-driven ROC activity, possibly 
via TRP channels. This study, however, did not 
identify the exact molecular species responsible for 
ROC activation. In addition to AA, the other product 
of cPLA2 reaction, a lysophospholipid (probably 
LPC), might act as a substrate for LPA production. 
LPA is known to activate some TRP channels. It 
is of interest to clarify this in detail. The molecular 
mechanism of cPLA2 activation also remained 
unresolved, although AA release was strongly 
blocked by an inhibitor of MEK1, an enzyme that 
regulates ERK1/2, known to phosphorylate and 
activate cPLA2. Further characterization of cPLA2 
is important to understand the mechanism by 
which OX1 (and GPCRs in general) couples with 
phospholipases.
OxA binding to OX1 also activated DAGL and 
the production of endocannabinoid 2-AG. This 
pathway is distinct from the pathway leading to 
AA release. CHO-hOX1 cells are able to produce 
biologically relevant amounts of 2-AG, as noted 
in the cell−cell communication assay developed. 
Following this study, the OX1 receptor joins 
various other Gq-coupled receptors able to induce 
endocannabinoid production. This result was 
somewhat expected, as GPCR signaling-induced 
endocannabinoids are known to be retrograde 
regulators of synaptic transmission. However, several 
redundant physiological functions of orexinergic 
and endocannabinoid systems, especially in the 
regulation of food intake, make the hypothesis of 
2-AG acting as the combining molecule between 
these two central circuits plausible (Figure 5.).
Feed-forward signaling loops appear to be 
characteristic for OX1 signaling. OX1-induced AA 
release is dependent on Ca2+ influx (Paper I), and AA 
was shown to contribute to Ca2+ influx (Paper III). 
Similarly, OX1-activated PLD1 ( Jantti et al., 2011) 
theoretically activates itself (see section 1.4.2.4.2.). 
Coexpression of OX1 and CB1 receptors in the same 
cells induces highly potent MAPK activation after 
OxA stimulation (Hilairet et al., 2003). Finally, OX 
neurons also express receptors for orexins and are 
depolarized by orexin (Yamanaka et al., 2010). It is 
tempting to speculate that the central role of orexins 
in maintaining arousal is based, at least in part, on the 
built-in feed-forward mechanisms of orexin receptor 
signaling pathways.
The filtration method developed can be used at a 
semi-high-throughput scale to assess the stimulus-
activated release of AA (and other secreted 
compounds combined with a suitable detection 
system), with or without inhibitors of interest. It is 
very efficient and easy to perform. The only special 
requirements are the filter-bottomed 96-well plates 
and compatible vacuum manifold or centrifuge with 
96-well plate adaptors. The equipment is inexpensive 
and the method easy to set up in a standard 
laboratory.
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